WO2023001288A1 - 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 - Google Patents

整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 Download PDF

Info

Publication number
WO2023001288A1
WO2023001288A1 PCT/CN2022/107388 CN2022107388W WO2023001288A1 WO 2023001288 A1 WO2023001288 A1 WO 2023001288A1 CN 2022107388 W CN2022107388 W CN 2022107388W WO 2023001288 A1 WO2023001288 A1 WO 2023001288A1
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
eye
seq
antagonist
antigen
Prior art date
Application number
PCT/CN2022/107388
Other languages
English (en)
French (fr)
Inventor
杨少伟
俞金泉
李胜峰
Original Assignee
百奥泰生物制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 百奥泰生物制药股份有限公司 filed Critical 百奥泰生物制药股份有限公司
Publication of WO2023001288A1 publication Critical patent/WO2023001288A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Definitions

  • the invention belongs to the field of biomedicine, and particularly relates to the application of an integrin GPIIb/IIIa antagonist and its combination with anti-VEGF antibody.
  • Macular degeneration is a medical condition found primarily in older adults in which the center lining of the eye, known as the macular area of the retina, becomes thinned, shrinks, and in some cases bleeds. This can lead to loss of central vision, which prevents patients from seeing finer details.
  • macular degeneration is the leading cause of central vision loss (blindness) in older adults.
  • the term usually refers to age-related macular degeneration (AMD), although some macular dystrophies that affect young people are sometimes called macular degeneration.
  • Age-related macular degeneration is a disease of irreversible vision loss or loss caused by the degeneration of retinal pigment epithelium and neuroretina. It mostly occurs in patients over 50 years old. Both eyes develop successively or simultaneously, and progressively damage vision. It is a fundus lesion that seriously threatens the visual function of the elderly. With the aging of the population, it has become the first blinding eye disease in Western countries, and its incidence is gradually increasing in Asia.
  • the invention discloses a method or use of an integrin GPIIb/IIIa antagonist for treating eye diseases.
  • the method or use comprises: administering an effective amount of an integrin GPIIb/IIIa antagonist to a patient in need thereof.
  • the present invention discloses the application of integrin GPIIb/IIIa antagonist in the preparation of medicine for treating eye diseases.
  • the present invention also discloses a kit, which includes an antagonist of integrin GPIIb/IIIa (or preparation), and instructions for guiding patients in need to administer the antagonist of integrin GPIIb/IIIa (or preparation). manual.
  • the ocular disease is an ocular disease with VEGF overexpression, such as fundus lesions with VEGF overexpression.
  • the ocular disease is selected from macular degeneration, age-related macular degeneration (AMD), corneal neovascularization, diseases associated with corneal neovascularization, retinal neovascularization, retinal/choroidal neovascularization choroidal neovascularization secondary to pathological myopia, iris neovascularization, intraocular neovascularization, ocular neovascular disease, neovascular glaucoma, macular edema, diabetic macular edema (DME, including focal, non-central DME and Diffuse, including central DME), cystoid macular edema (CME), retinopathy, diabetic retinopathy (DR, including proliferative DR (PDR), non-proliferative DR (NPDR), and high-altitude
  • the present invention discloses ophthalmic pharmaceutical compositions comprising an integrin GPIIb/IIIa antagonist.
  • ophthalmic pharmaceutical compositions further include a pharmaceutically acceptable carrier.
  • integrin GPIIb/IIIa antagonists or pharmaceutical compositions thereof are used to enhance VEGF antagonists (e.g., anti-VEGF antibodies or antigen-binding fragments, aflibercept) in the treatment of ocular diseases such as VEGF overexpressed ocular diseases. Use in Effects of Disease.
  • VEGF antagonists e.g., anti-VEGF antibodies or antigen-binding fragments, aflibercept
  • the present invention discloses a method of combining VEGF antagonists (such as anti-VEGF antibodies or antigen-binding fragments, aflibercept) and integrin GPIIb/IIIa antagonists to treat ocular diseases such as ocular diseases with VEGF overexpression or use.
  • the method or use comprises: administering to a patient in need thereof an effective amount of a VEGF antagonist (eg, an anti-VEGF antibody or antigen-binding fragment, aflibercept) and an integrin GPIIb/IIIa antagonist.
  • the present invention discloses VEGF antagonists (such as anti-VEGF antibodies or antigen-binding fragments, aflibercept) and integrin GPIIb/IIIa antagonists in the preparation of ophthalmic diseases such as VEGF overexpressed eye diseases application in medicines.
  • VEGF antagonists such as anti-VEGF antibodies or antigen-binding fragments, aflibercept
  • integrin GPIIb/IIIa antagonists in the preparation of ophthalmic diseases such as VEGF overexpressed eye diseases application in medicines.
  • the present invention also discloses a kit comprising a VEGF antagonist (such as an anti-VEGF antibody or an antigen-binding fragment, aflibercept) (or a preparation), an integrin GPIIb/IIIa antagonist (or a preparation) ), and instructions for instructing patients in need to administer VEGF antagonists (such as anti-VEGF antibodies or antigen-binding fragments, aflibercept) (or preparations) and integrin GPIIb/IIIa antagonists (or preparations).
  • a VEGF antagonist such as an anti-VEGF antibody or an antigen-binding fragment, aflibercept
  • an integrin GPIIb/IIIa antagonist or a preparation
  • the invention also discloses a kit comprising a combination of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) and an integrin GPIIb/IIIa antagonist (or preparation), and instructions for instructing patients in need of administering the composition (or preparation) of a VEGF antagonist (such as an anti-VEGF antibody or antigen-binding fragment, aflibercept) and an integrin GPIIb/IIIa antagonist.
  • a VEGF antagonist e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • an integrin GPIIb/IIIa antagonist or preparation
  • the present invention also discloses a pharmaceutical composition suitable for injection comprising a VEGF antagonist (such as an anti-VEGF antibody or antigen-binding fragment, aflibercept) and an integrin GPIIb/IIIa antagonist.
  • a VEGF antagonist such as an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the mass ratio of the VEGF antagonist to the integrin GPIIb/IIIa antagonist is (0.5-7):1.
  • the mass ratio of the VEGF antagonist to the integrin GPIIb/IIIa antagonist is (1-7):1.
  • the mass ratio of the VEGF antagonist to the integrin GPIIb/IIIa antagonist is (1-4):1.
  • the mass ratio of the VEGF antagonist to the integrin GPIIb/IIIa antagonist is 1:1.
  • the mass ratio of the VEGF antagonist to the integrin GPIIb/IIIa antagonist is 2:1. In some embodiments, the mass ratio of the VEGF antagonist to the integrin GPIIb/IIIa antagonist is 4:1.
  • the pharmaceutical composition comprises at least 0.1% of a VEGF antagonist (eg, anti-VEGF antibody or antigen-binding fragment, aflibercept) and 0.1% of an integrin GPIIb/IIIa antagonist.
  • the percentages of VEGF antagonist (eg, anti-VEGF antibody or antigen-binding fragment, aflibercept) and integrin GPIIb/IIIa antagonist can vary and can be between about 2% and about 90% by weight of a given dosage form.
  • the VEGF antagonist (eg, anti-VEGF antibody or antigen-binding fragment, aflibercept) and the integrin GPIIb/IIIa antagonist may be administered in effective amounts in such therapeutically useful pharmaceutical compositions.
  • the present invention also discloses the preparation method of the above-mentioned pharmaceutical composition: separately mix VEGF antagonist (such as anti-VEGF antibody or antigen-binding fragment, aflibercept) and integrin GPIIb/IIIa antagonist (or VEGF antagonist (such as the composition of anti-VEGF antibody or antigen-binding fragment, aflibercept) and integrin GPIIb/IIIa antagonist) are mixed with a pharmaceutically acceptable carrier suitable for injection (such as water for injection, physiological saline, etc.).
  • a pharmaceutically acceptable carrier suitable for injection such as water for injection, physiological saline, etc.
  • Mixing methods of VEGF antagonists (such as anti-VEGF antibodies or antigen-binding fragments, aflibercept) and integrin GPIIb/IIIa antagonists with pharmaceutically acceptable carriers are generally known in the art.
  • the present invention also discloses the use of VEGF antagonists (such as anti-VEGF antibody or antigen-binding fragment, aflibercept) and integrin GPIIb/IIIa antagonists in the preparation of eye diseases such as VEGF overexpression.
  • VEGF antagonists such as anti-VEGF antibody or antigen-binding fragment, aflibercept
  • integrin GPIIb/IIIa antagonists in the preparation of eye diseases such as VEGF overexpression.
  • a VEGF antagonist eg, anti-VEGF antibody or antigen-binding fragment, aflibercept
  • an integrin GPIIb/IIIa antagonist for the treatment of ocular diseases such as VEGF overexpressed ocular diseases.
  • the present invention uses VEGF antagonists (such as anti-VEGF antibodies or antigen-binding fragments, aflibercept) (or preparations) and integrin GPIIb/IIIa antagonists (or preparations) for ocular diseases such as ocular diseases with VEGF overexpression Symptoms can be alleviated during treatment.
  • VEGF antagonists eg, anti-VEGF antibodies or antigen-binding fragments, aflibercept
  • integrin GPIIb/IIIa antagonists or formulations
  • ocular Diseases such as ocular diseases with overexpression of VEGF, such as surgery, laser therapy, physical rehabilitation and drug therapy (such as aflibercept Conbercept )Wait.
  • the VEGF antagonist is an anti-VEGF antibody or antigen-binding fragment.
  • the anti-VEGF antibody or antigen-binding fragment at least comprises HCDR1 shown in SEQ ID NO:1, HCDR2 shown in SEQ ID NO:2, HCDR3 shown in SEQ ID NO:3, SEQ ID NO One or more of LCDR1 shown in :4, LCDR2 shown in SEQ ID NO:5, and LCDR3 shown in SEQ ID NO:6.
  • the anti-VEGF antibody or antigen-binding fragment comprises HCDR1 shown in SEQ ID NO:1, HCDR2 shown in SEQ ID NO:2, HCDR3 shown in SEQ ID NO:3, SEQ ID NO: LCDR1 shown in 4, LCDR2 shown in SEQ ID NO:5, and LCDR3 shown in SEQ ID NO:6.
  • the heavy chain variable region of the anti-VEGF antibody or antigen-binding fragment comprises, or is at least 80% identical to, the sequence set forth in SEQ ID NO:7 or an amino acid sequence having one or more conservative amino acid substitutions compared to the sequence shown in SEQ ID NO:7; and/or
  • the light chain variable region of the anti-VEGF antibody or antigen-binding fragment comprises the sequence shown in SEQ ID NO: 8, or a sequence having at least 80% identity compared with the sequence shown in SEQ ID NO: 8, or a sequence with SEQ ID NO: 8.
  • the heavy chain variable region of the anti-VEGF antibody or antigen-binding fragment comprises the sequence shown in SEQ ID NO: 7
  • the light chain variable region of the anti-VEGF antibody or antigen-binding fragment comprises SEQ ID The sequence shown in NO:8.
  • the heavy chain of the anti-VEGF antibody comprises the sequence set forth in SEQ ID NO:9, or a sequence at least 80% identical to the sequence set forth in SEQ ID NO:9, or identical to the sequence set forth in SEQ ID NO:9.
  • the light chain of the anti-VEGF antibody comprises the sequence shown in SEQ ID NO: 10, or a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 10, or compared with the sequence shown in SEQ ID NO: 10 An amino acid sequence having one or more conservative amino acid substitutions.
  • the heavy chain of the anti-VEGF antibody comprises the sequence shown in SEQ ID NO:9
  • the light chain of the anti-VEGF antibody comprises the sequence shown in SEQ ID NO:10.
  • the VEGF antagonist is selected from an anti-VEGF antibody or antigen-binding fragment, an anti-VEGF receptor antibody or antigen-binding fragment, a VEGF receptor fusion protein, an aptamer that specifically binds VEGF, and a VEGFR tyrosine kinase inhibitor agent.
  • the anti-VEGF antibody is brucetizumab, bevacizumab, ranibizumab or the monoclonal antibody BAT5906 disclosed in ZL201910585853.9.
  • bevacizumab comprises or its biosimilars, such as Pubeixi, Park Xinting, Beianting, Arielto, Boyunuo, or BAT1706.
  • ranibizumab includes or its biosimilars.
  • the VEGF receptor fusion protein is selected from Aflibercept and Conbercept.
  • the aptamer that specifically binds to VEGF is peganib
  • the VEGFR tyrosine kinase inhibitor is selected from: 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethyl Oxy)quinazoline (ZD6474), 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy base) quinazoline (AZD2171), vatalanib (PTK787), semaxaminib (SU5416) and sunitinib
  • the VEGF antagonist protein can be expressed in cells such as CHO cells or HEK293 cells by genetic engineering, and obtained by purification; the purification can be performed by conventional methods, such as centrifuging the cell suspension and collecting the supernatant. Methods such as affinity columns and ion exchange columns can be used to further purify VEGF antagonist proteins.
  • the integrin GPIIb/IIIa antagonist is batifiban (XP2094 disclosed in ZL03112798.3) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutically acceptable salt of batifiban is an inorganic acid salt, and the inorganic acid can be: hypoiodous acid, hypochlorous acid, hypobromous acid, iodic acid, perchloric acid, peroxodisulfuric acid, Peroxydicarbonic acid, percarbonic acid, pyrophosphoric acid, pyrosulfuric acid, pyrosulfurous acid, tetrathionic acid, phosphoric acid, thiosulfuric acid, sulfuric acid, chloric acid, metaphosphoric acid, hydroiodic acid, hydrodiazic acid, hydrofluoric acid, hydrosulfuric acid , hydrochloric acid, hydrobromic acid, tetraboric acid, carbonic acid, nitric acid, bromic acid, sulfurous acid
  • the pharmaceutically acceptable salt of batifiban is an organic acid salt
  • the organic acid can be: tartaric acid, oxalic acid, malic acid, citric acid (citric acid), ascorbic acid, benzoic acid, salicylic acid , caffeic acid, lactic acid, sorbic acid, fumaric acid, formic acid, acetic acid, benzoic acid, oxalic acid, succinic acid, pyruvic acid, ⁇ -ketosuccinic acid, benzenesulfonic acid, or trifluoroacetic acid, maleic acid, tetra Sulfonic acid, methanesulfonic acid, fumaric acid, amino acid, etc.
  • the organic acid is citric acid (citric acid), malic acid, lactic acid, acetic acid, oxalic acid, amino acids.
  • the pharmaceutically acceptable salt of batifiban is citrate.
  • the pharmaceutically acceptable salt of batifiban is batifiban combined with a metal ion (for example, an alkali metal ion (such as sodium or potassium), an alkaline earth metal ion (such as calcium or magnesium) or an aluminum ion. ) or salts formed with organic bases (such as diethanolamine, triethanolamine, N-methylglucamine) and the like.
  • the present invention discloses a method for treating ocular diseases, such as VEGF overexpressed ocular diseases, in a patient in need thereof, comprising administering an effective amount of a VEGF antagonist (such as an anti-VEGF antibody or an antigen-binding fragment, aflibercept) and batifiban or a pharmaceutically acceptable salt thereof, wherein the effective amount of the VEGF antagonist (such as an anti-VEGF antibody or antigen-binding fragment, aflibercept) administered is about 0.1 mg to 15 mg per treatment cycle.
  • a VEGF antagonist such as an anti-VEGF antibody or an antigen-binding fragment, aflibercept
  • a treatment cycle is 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 5 weeks, 6 weeks, 7 weeks, or a range between any two of these values (including endpoint) or any value in it.
  • the VEGF antagonist is an anti-VEGF antibody or antigen-binding fragment.
  • the anti-VEGF antibody is antibody BAT5906.
  • the VEGF antagonist is aflibercept.
  • a VEGF antagonist such as an anti-VEGF antibody (such as antibody BAT5906) or antigen-binding fragment, aflibercept) and batifiban or a pharmaceutically acceptable salt thereof (or a VEGF antagonist (for example, anti-VEGF antibody or antigen-binding fragment, aflibercept) and batifiban or a pharmaceutically acceptable salt thereof) are formulated into a pharmaceutical composition, and are supplied to the drug in various forms suitable for the selected route of administration. Administration to the patient, for example, by topical application to the eye, injection around the eye, or intraocular injection.
  • VEGF antagonists such as anti-VEGF antibodies or antigen-binding fragments, aflibercept
  • batifiban or a pharmaceutically acceptable salt thereof or preparations
  • batifiban or a pharmaceutically acceptable salt thereof or preparations
  • batifiban or a pharmaceutically acceptable salt thereof is administered by intravitreal injection.
  • Dosage of VEGF antagonist e.g.
  • anti-VEGF antibody or antigen-binding fragment, aflibercept and batifiban or its pharmaceutically acceptable salt will depend on the nature of the drug, the cell surface triggering drug internalization, transport and release The extent of the disease, the disease being treated, the condition of the patient (such as age, sex, weight, etc.).
  • the mass ratio of doses of the VEGF antagonist to the integrin GPIIb/IIIa antagonist is (0.5-7):1. In some embodiments, the mass ratio of doses of the VEGF antagonist to the integrin GPIIb/IIIa antagonist is (1-7):1. In some embodiments, the mass ratio of doses of the VEGF antagonist to the integrin GPIIb/IIIa antagonist is (1-4):1. In some embodiments, the doses of the VEGF antagonist and the integrin GPIIb/IIIa antagonist are in a mass ratio of 1:1. In some embodiments, the VEGF antagonist and integrin GPIIb/IIIa antagonist doses are in a 2:1 mass ratio. In some embodiments, the VEGF antagonist and integrin GPIIb/IIIa antagonist doses are in a 4:1 mass ratio.
  • the VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • the VEGF antagonist is about 0.1 mg/eye to 7.5 mg/eye or more of the VEGF antagonist per administration.
  • aflibercept e.g. anti-VEGF antibody or antigen-binding fragment, aflibercept.
  • Formulations containing VEGF antagonists e.g. anti-VEGF antibodies or antigen-binding fragments, aflibercept
  • suitable carriers include physiological saline or bacteriostatic water and the like.
  • the formulation comprises at least 0.1% of a VEGF antagonist (eg, anti-VEGF antibody or antigen-binding fragment, aflibercept).
  • the percentage of antibody can vary and can range from about 2% to 90% by weight of a given dosage form.
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the VEGF antagonist (e.g., anti-VEGF antibody or antigen-binding fragment, aflibercept) is about 0.1 mg/eye, about 0.2 mg/eye, about 0.3 mg/eye, about 0.5 mg per administration /eye, about 0.9mg/eye, about 1mg/eye, about 1.25mg/eye, about 2mg/eye, about 2.5mg/eye, about 3mg/eye, about 4mg/eye, about 5mg/eye, about 6mg/eye , about 7.5 mg/eye, or a range between any two of these values (inclusive), or any value therein, or a dose of a VEGF antagonist (eg, anti-VEGF antibody or antigen-binding fragment, aflibercept) preparations.
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the VEGF antagonist eg, anti-VEGF antibody (eg, antibody BAT5906) or antigen-binding fragment, aflibercept
  • the VEGF antagonist is administered at an effective dose of about 0.1 mg to 15 mg per dose.
  • the VEGF antagonist e.g., anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist is administered at an effective dose of about 0.1 mg to 8 mg per dose.
  • the VEGF antagonist eg, anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist e.g., an anti-VEGF antibody (such as antibody BAT5906) or antigen-binding fragment, aflibercept
  • the VEGF antagonist is administered in an effective amount of 0.1 mg to 15 mg every 2 weeks, 3 weeks, 4 weeks, 5 weeks or once every 6 weeks.
  • the VEGF antagonist eg, anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist is administered in an effective amount of about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.6 mg, about 1mg, about 1.25mg, about 2mg, about 2.5mg, about 3mg, about 4mg, about 4.5mg, about 5mg, about 6mg, about 7mg, about 8mg, about 9mg, about 10mg, about 11mg, about 12mg, about 13mg, About 14 mg, about 15 mg (or a range between any two of these values, inclusive, or any value therein) every 2, 3, 4, 5 or 6 weeks.
  • the VEGF antagonist (e.g., anti-VEGF antibody or antigen-binding fragment, aflibercept) is administered in an effective amount of about 0.2 mg, about 0.3 mg, about 0.6 mg, about 1 mg, about 1.25 mg, about 2 mg , about 2.5 mg, about 4 mg, about 5 mg or about 8 mg every 3 weeks, 4 weeks or 5 weeks.
  • the VEGF antagonist (eg, anti-VEGF antibody or antigen-binding fragment, aflibercept) is administered in an effective amount of about 9 mg, about 10 mg, about 11 mg, 12 mg, about 13 mg, about 14 mg, about 15 mg per 3 Once a week, 4 weeks or 5 weeks.
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • antibody BAT5906 is administered in an effective amount of about 1-5 mg/eye every 4 weeks. In some embodiments, the effective amount of antibody BAT5906 administered is about 1 mg/eye, about 1.25 mg/eye, about 2 mg/eye, about 2.5 mg/eye, or about 4 mg/eye once every 4 weeks.
  • VEGF antagonist eg, anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the administration cycles of batifiban or a pharmaceutically acceptable salt thereof and VEGF antagonist (such as anti-VEGF antibody or antigen-binding fragment, aflibercept) may be the same or different.
  • the VEGF antagonist (eg, anti-VEGF antibody or antigen-binding fragment, aflibercept) and batifiban or a pharmaceutically acceptable salt thereof can be administered in the same or different ways.
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the anti-VEGF antibody or antigen-binding fragment is administered by intravitreal injection.
  • aflibercept is administered by intravitreal injection.
  • batifiban or a pharmaceutically acceptable salt thereof is administered by instillation into the conjunctival sac.
  • batifiban or a pharmaceutically acceptable salt thereof is administered by intravitreal injection.
  • the VEGF antagonist such as an anti-VEGF antibody (such as antibody BAT5906) or antigen-binding fragment, aflibercept) and batifiban or a pharmaceutically acceptable salt thereof are separate dosage units , Combined medication.
  • the VEGF antagonist eg, anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the VEGF antagonist such as an anti-VEGF antibody (such as antibody BAT5906) or antigen-binding fragment, aflibercept) and batifiban or a pharmaceutically acceptable salt thereof simultaneously form a combined administration unit, Combination medication.
  • a combination of a VEGF antagonist eg, an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • batifiban or a pharmaceutically acceptable salt thereof is administered by intravitreal injection.
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the ocular disease with overexpression of VEGF is a fundus lesion with overexpression of VEGF.
  • the ocular disease in which VEGF is overexpressed is selected from the group consisting of macular degeneration, age-related macular degeneration (AMD), corneal neovascularization, diseases associated with corneal neovascularization, retinal neovascularization, retinal/choroidal Diseases related to neovascularization, choroidal neovascularization secondary to pathological myopia, iris neovascularization, intraocular neovascularization, ocular neovascular disease, neovascular glaucoma, macular edema, diabetic macular edema (DME, including local, Non-central DME and diffuse, including central DME), cystoid macular edema (CME), retinopathy, diabetic retinopathy (DR, including proliferative DR (PDR), non-prolife
  • DME diabetic ma
  • an effective amount of batifiban or a pharmaceutically acceptable salt thereof administered is about 0.1 mg to 6 mg per treatment cycle.
  • a treatment cycle is 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 5 weeks, 6 weeks, 7 weeks, or a range between any two of these values (including endpoint) or any value in it.
  • an effective amount of batifiban or a pharmaceutically acceptable salt thereof administered is about 0.1 mg to 3 mg once every 3, 4, or 5 weeks.
  • an effective amount of batifiban or a pharmaceutically acceptable salt thereof administered is about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.6 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg (or a range between any two of these values (inclusive) or any value therein) every 3 weeks, every 4 weeks or every 5 weeks.
  • the effective amount of batifiban or a pharmaceutically acceptable salt thereof administered is about 3 mg to about 6 mg once every 3, 4, or 5 weeks.
  • an effective amount of batifiban or a pharmaceutically acceptable salt thereof administered is about 3.1 mg, about 3.5 mg, about 4 mg, about 4.6 mg, about 5 mg, about 5.3 mg, about 6 mg (or these values The range between any two values in (inclusive) or any value therein) every 3, 4, or 5 weeks.
  • the present invention discloses a method of treating ocular diseases, such as VEGF overexpressed ocular diseases, comprising administering to a patient in need thereof an effective amount of a VEGF antagonist (such as an anti-VEGF antibody or antigen-binding fragment , aflibercept) (or preparations) and batifiban (or preparations); wherein, the effective amount of a VEGF antagonist (such as an anti-VEGF antibody or antigen-binding fragment, aflibercept) is about 0.1 in a single administration mg/eye to 7.5 mg/eye (or formulations containing such doses of VEGF antagonists (such as anti-VEGF antibodies or antigen-binding fragments, aflibercept)).
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the effective amount of batifiban is about 0.1 mg/eye to 3 mg/eye in a single administration (or a formulation containing this dose of batifiban).
  • Dosage schedule and mode of administration depend on benefit-risk of batifiban (or formulation), VEGF antagonists (e.g., anti-VEGF antibody or antigen-binding fragment, aflibercept) (or formulation) in certain patient populations Assessment and general clinical practice guidelines.
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept) of about 0.1 mg to 15 mg (or inclusive) per treatment cycle.
  • a VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • the effective amount of batifiban administered in each treatment cycle of the patient is about 0.1 mg to 6 mg (or containing this dose of batifiban Class preparations).
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept) of about 0.1 mg, about 0.2 mg, about 0.3 mg per cycle of treatment.
  • a VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • a treatment cycle is administered once from 1 week to 7 weeks.
  • an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) administered per treatment cycle is about 0.1 mg to 8 mg, or at or including such a dose of a VEGF antagonist (e.g., anti-VEGF antibody or antigen-binding fragment, aflibercept).
  • VEGF antibody or antigen-binding fragment, aflibercept VEGF antibody or antigen-binding fragment, aflibercept
  • one treatment cycle is about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, or range between any two of these values, inclusive, or any value therein.
  • one treatment cycle is about 2 weeks, about 3 weeks, about 4 weeks, or about 5 weeks.
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) of about 8 mg to about 15 mg per cycle of treatment, or a dose containing the VEGF antagonist (e.g., A preparation of an anti-VEGF antibody or antigen-binding fragment, aflibercept); wherein one treatment cycle is about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, or the range between any two of these values (inclusive), or any value therein.
  • a VEGF antagonist e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • a dose containing the VEGF antagonist e.g., A preparation of an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) of about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.6 mg per treatment cycle , about 1 mg, about 1.25 mg, about 2 mg, about 2.5 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 14 mg, about 15 mg , or a range (inclusive) between any two of these values, or any value therein, or a formulation containing such a dose of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept); wherein, A treatment cycle is about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks or about 6 weeks.
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept) of about 0.2 mg to 0.9 mg, or containing VEGF, per cycle of treatment.
  • a VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • Dosage Formulation of VEGF antagonist eg, anti-VEGF antibody or antigen-binding fragment, aflibercept
  • VEGF antagonist for example, about 0.6 mg (0.3 mg/eye) administered once.
  • the patient is administered an effective amount of about 0.6 mg of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) per treatment cycle, or a dose containing the VEGF antagonist (e.g., an anti-VEGF Antibody or antigen-binding fragment, aflibercept); wherein one treatment cycle is about 3 weeks, about 4 weeks or about 5 weeks.
  • a VEGF antagonist e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept) in an amount of about 1 mg to 1.3 mg, or inclusive, per treatment cycle.
  • a VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • Preparations of VEGF antagonists such as anti-VEGF antibody or antigen-binding fragment, aflibercept
  • about 1.2 mg 0.6 mg/eye
  • the patient is administered an effective amount of about 1.2 mg of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) per treatment cycle, or a dose containing the VEGF antagonist (e.g., an anti-VEGF Antibody or antigen-binding fragment, aflibercept); wherein one treatment cycle is about 3 weeks, about 4 weeks or about 5 weeks.
  • a VEGF antagonist e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept) in the range of about 1.5 mg to 3 mg, or inclusive, per cycle of treatment.
  • a VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • Preparations of VEGF antagonists such as anti-VEGF antibody or antigen-binding fragment, aflibercept
  • about 2 mg (1 mg/eye) or about 2.5 mg (1.25 mg/eye) is administered once.
  • the patient is administered an effective amount of about 2 mg or about 2.5 mg of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) per treatment cycle, or a dose containing the VEGF antagonist (for example, preparations of anti-VEGF antibody or antigen-binding fragment, aflibercept); wherein, one treatment cycle is about 3 weeks, about 4 weeks or about 5 weeks.
  • a VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept) of about 3 mg to 6 mg per cycle of treatment, or a dose containing VEGF Preparations of antagonists (such as anti-VEGF antibody or antigen-binding fragment, aflibercept); for example, about 4 mg (2 mg/eye) is administered once.
  • a VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • an anti-VEGF antibody e.g., antibody BAT5906
  • antigen-binding fragment, aflibercept antigen-binding fragment, aflibercept
  • the patient is administered an effective amount of about 4 mg of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) per treatment cycle, or a dose containing the VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept); wherein one treatment cycle is about 3 weeks, about 4 weeks or about 5 weeks.
  • a VEGF antagonist e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept) of about 6 mg to 9 mg, or a dose containing VEGF, per cycle of treatment.
  • a VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • Preparations of antagonists such as anti-VEGF antibody or antigen-binding fragment, aflibercept
  • about 8 mg (4 mg/eye) is administered once.
  • the patient is administered an effective amount of about 8 mg of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) per treatment cycle, or a dose containing the VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept); wherein one treatment cycle is about 3 weeks, about 4 weeks or about 5 weeks.
  • a VEGF antagonist e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept) of about 9 mg to 11 mg, or a dose containing VEGF, per cycle of treatment.
  • a VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • Preparations of antagonists such as anti-VEGF antibody or antigen-binding fragment, aflibercept
  • about 10 mg (5 mg/eye) is administered once.
  • the patient is administered an effective amount of about 10 mg of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) per treatment cycle, or a dose containing the VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept); wherein one treatment cycle is about 3 weeks, about 4 weeks or about 5 weeks.
  • a VEGF antagonist e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the patient is administered an effective amount of a VEGF antagonist (e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept) of about 13 mg to 15.2 mg, or a dose comprising, per treatment cycle.
  • a VEGF antagonist e.g., an anti-VEGF antibody (e.g., antibody BAT5906) or antigen-binding fragment, aflibercept
  • Preparations of VEGF antagonists such as anti-VEGF antibody or antigen-binding fragment, aflibercept
  • about 15 mg 7.5 mg/eye
  • the patient is administered an effective amount of about 15 mg of a VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept) per treatment cycle, or a dose containing VEGF antagonist (e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept); wherein one treatment cycle is about 3 weeks, about 4 weeks or about 5 weeks.
  • a VEGF antagonist e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the effective amount of a VEGF antagonist is about 0.1 mg to 15 mg once every 4 weeks.
  • the effective amount of the VEGF antagonist is about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.6 mg, about 1 mg , about 1.25 mg, about 2 mg, about 2.5 mg, about 3 mg, about 4 mg, about 5 mg, about 160 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 14 mg, about 15 mg every 3 or 4 weeks.
  • the effective amount of the VEGF antagonist is about 0.1 mg/eye, about 0.15 mg/eye, about 0.2 mg/eye, about 0.3 mg/eye Eye, about 0.5mg/eye, about 0.6mg/eye, about 1mg/eye, about 1.25mg/eye, about 1.5mg/eye, about 2mg/eye, about 2.5mg/eye, about 3mg/eye, about 3.5mg /eye, about 4mg/eye, about 4.5mg/eye, about 5mg/eye, about 5.5mg/eye, about 6mg/eye, about 7mg/eye, about 7.5mg/eye once every 3 or 4 weeks.
  • the VEGF antagonist eg, anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the effective amount of the VEGF antagonist is about 0.2 mg/eye, about 0.3 mg/eye, about 0.5 mg/eye, about 0.6 mg/eye Eye, about 1 mg/eye, about 1.25 mg/eye, about 1.5 mg/eye, about 2 mg/eye, about 2.5 mg/eye, about 3 mg/eye, about 3.5 mg/eye, about 4 mg/eye once every 4 weeks.
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • the patient is administered an effective amount of batifiban of about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.6 mg, about 1 mg, about 1.25 mg, about 1.5 mg per treatment cycle. mg, about 2 mg, about 2.5 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, or a range between any two of these values (inclusive) or any value therein, or containing such doses of batifiban preparations.
  • a treatment cycle is administered once from 1 week to 7 weeks.
  • the effective amount of batifiban administered in each treatment cycle is about 0.1 mg to 3 mg, or a formulation containing this dose of batifiban; wherein, a treatment cycle is about 1 to 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, or a range between any two of these values (inclusive) or any value therein.
  • one treatment cycle is about 3 weeks, about 4 weeks, or about 5 weeks.
  • the patient is administered with an effective amount of batifiban of about 3 mg to about 6 mg in each treatment cycle, or a preparation containing this dose of batifiban; wherein, a treatment cycle is about 3 weeks, about 4 weeks weeks or about 5 weeks.
  • the effective amount of batifiban administered to the patient per treatment cycle is about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.6 mg, about 1 mg, about 1.25 mg, about 1.5 mg, about 2 mg , about 2.5 mg, about 3 mg, or a range between any two of these values (inclusive) or any value therein, or a formulation containing this dose of batifiban; wherein one treatment cycle is about 3 weeks , about 4 weeks or about 5 weeks.
  • the effective amount of batifiban administered to the patient per treatment cycle is about 0.1 mg to 0.22 mg, or a formulation containing this dose of batifiban; for example, about 0.2 mg (0.1 mg/eye) Medicine 1 time.
  • the patient is administered an effective amount of batifiban of about 0.2 mg per treatment cycle, or a formulation containing such a dose of batifiban; wherein, a treatment cycle is about 3 weeks, about 4 weeks, or About 5 weeks.
  • the effective amount of batifiban administered to the patient per treatment cycle is about 0.2 mg to 0.38 mg, or a formulation containing this dose of batifiban; for example, about 0.3 mg (0.15 mg/eye) Medicine 1 time.
  • the patient is administered an effective amount of batifiban of about 0.3 mg per treatment cycle, or a formulation containing such a dose of batifiban; wherein, a treatment cycle is about 3 weeks, about 4 weeks, or 4 weeks.
  • the effective amount of batifiban administered to the patient per treatment cycle is about 0.3 mg to 0.5 mg, or a formulation containing this dose of batifiban; for example, about 0.4 mg (0.2 mg/eye). Medicine 1 time.
  • the patient is administered an effective amount of batifiban of about 0.4 mg per treatment cycle, or a formulation containing such a dose of batifiban; wherein, a treatment cycle is about 3 weeks, about 4 weeks, or About 5 weeks.
  • the patient is administered an effective amount of batifiban of about 1 mg to 1.4 mg per treatment cycle, or a formulation containing such a dose of batifiban; for example, about 1.2 mg (0.6 mg/eye) is administered 1 time.
  • the patient is administered an effective amount of batifiban of about 1.2 mg per treatment cycle, or a formulation containing such a dose of batifiban; wherein, a treatment cycle is about 3 weeks, about 4 weeks, or About 5 weeks.
  • the patient is administered an effective amount of batifiban of about 1.6 mg to 2.1 mg per treatment cycle, or a formulation containing such a dose of batifiban; for example, about 2 mg (1 mg/eye) is administered 1 Second-rate.
  • the effective amount of batifiban administered to the patient in each treatment cycle is about 2 mg, or a formulation containing this dose of batifiban; wherein, a treatment cycle is about 3 weeks, about 4 weeks or about 5 weeks.
  • the patient is administered an effective amount of batifiban of about 2.2 mg to 3 mg per treatment cycle, or a formulation containing such a dose of batifiban; for example, about 2.5 mg (1.25 mg/eye) is administered 1 time.
  • the patient is administered an effective amount of batifiban of about 2.5 mg per treatment cycle, or a formulation containing such a dose of batifiban; wherein, a treatment cycle is about 3 weeks, about 4 weeks, or About 5 weeks.
  • the patient is administered an effective amount of batifiban of about 2.4 mg to 4 mg per treatment cycle, or a formulation containing such a dose of batifiban; for example, about 3 mg (1.5 mg/eye) is administered 1 Second-rate.
  • the effective amount of batifiban administered to the patient in each treatment cycle is about 3 mg, or a formulation containing this dose of batifiban; wherein, a treatment cycle is about 3 weeks, about 4 weeks or about 5 weeks.
  • the patient is administered a VEGF antagonist (e.g., anti-VEGF antibody or antigen-binding fragment, aflibercept) and batifiban (or a VEGF antagonist (e.g., anti-VEGF antibody) once per treatment cycle, respectively.
  • VEGF antibody or antigen-binding fragment, aflibercept and batifiban.
  • the VEGF antagonist e.g., anti-VEGF antibody or antigen-binding fragment, aflibercept
  • batifiban or VEGF antagonist (e.g., anti-VEGF antibody or antigen-binding fragment, aflibercept) and batifiban)
  • 2 times, 3 times, 4 times or 5 times for example 2 times, 3 times, 4 times or 5 times.
  • the patient can only be dosed 1, 2, 3, 4, 5 or 6 times per treatment cycle.
  • the VEGF antagonist is an anti-VEGF antibody (eg, antibody BAT5906) or an antigen-binding fragment.
  • the VEGF antagonist is aflibercept.
  • administering one or more times is relative to each eye of the patient.
  • both eyes of the patient suffer from ocular diseases with overexpression of VEGF, and "administration once" means that both eyes need to be administered once.
  • only one eye of the patient suffers from ocular diseases related to VEGF, and one administration refers to one administration in one eye.
  • the patient is treated for one treatment cycle. In some embodiments, the patient receives multiple (e.g., 2, 3, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 , 14, 15, 16 or 17) treatment cycles. In some embodiments, the patient is treated until the condition is in remission and no longer requires treatment.
  • the present invention discloses a method for treating eye diseases with overexpression of VEGF, the method comprising: administering about 0.1 mg/eye to 1.25 mg/eye, about 1.25 mg /eye to 2.5mg/eye, about 2.5mg/eye to 4mg/eye, about 4mg/eye to 6mg/eye, about 6mg/eye to 7.5mg/eye, such as about 0.1mg/eye, 0.2mg/eye, 0.3 mg/eye, 0.4mg/eye, 0.5mg/eye, 0.6mg/eye, 0.8mg/eye, 1mg/eye, 1.25mg/eye, 1.3mg/eye, 2mg/eye, 2.5mg/eye, 3mg/eye , 4mg/eye, 5mg/eye, 6mg/eye, 7.5mg/eye of VEGF antagonist (such as anti-VEGF antibody or antigen-binding fragment, aflibercept), or containing this dose of VEGF antagonist (such as anti-
  • the patient is treated with a single dose of a VEGF antagonist (eg, an anti-VEGF antibody or antigen-binding fragment, aflibercept) and batifiban.
  • a VEGF antagonist eg, an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • batifiban e.g., an anti-VEGF antibody or antigen-binding fragment, aflibercept
  • the VEGF antagonist e.g., anti-VEGF antibody or antigen-binding fragment, aflibercept
  • batifiban are administered every 3 or 4 weeks.
  • the patient's symptoms are relieved.
  • the patient's symptoms after a single dose of administration, the patient's symptoms have not been relieved as expected, and then about 0.1 mg/eye to 7.5 mg/eye of a VEGF antagonist (such as an anti-VEGF antibody or antigen-binding antibody) is administered to the patient separately or simultaneously. fragment, aflibercept) and about 0.1 mg/eye to 3 mg/eye batifiban.
  • a VEGF antagonist such as an anti-VEGF antibody or antigen-binding antibody
  • the anti-VEGF antibody is antibody BAT5906.
  • the present invention discloses a method for treating ocular diseases overexpressed by VEGF, said method comprising a single administration to a patient in need thereof, or administration once every week to every 7 weeks, or once every week 0.1 mg/eye to 7.5 mg/eye of antibody BAT5906 and 0.1 mg/eye to 3 mg/eye of batifiban were administered once every 3 or 4 weeks.
  • the method comprises a single administration to a patient in need thereof, or administration of 0.25 mg/eye, 0.3 mg/eye, 0.6 mg once every week to every 7 weeks, or once every 3 or 4 weeks Antibody BAT5906 per eye, 1 mg/eye, 1.25 mg/eye, 2 mg/eye, 2.5 mg/eye or 4 mg/eye, and batifiban at 1 mg/eye or 0.5 mg/eye.
  • the method comprises a single administration to a patient in need thereof, or administration of 0.25 mg/eye, 0.3 mg/eye, 0.6 mg once every week to every 7 weeks, or once every 3 or 4 weeks Antibody BAT5906 per eye, 1 mg/eye, 1.25 mg/eye, 2 mg/eye, 2.5 mg/eye or 4 mg/eye, and batifiban at 1.5 mg/eye or 3 mg/eye.
  • the present invention discloses a method for treating ocular diseases overexpressed by VEGF, said method comprising a single administration to a patient in need thereof, or administration once every week to every 7 weeks, or once every week Administer 0.1 mg/eye to 7.5 mg/eye of aflibercept and 0.1 mg/eye to 3 mg/eye of batifiban once every 3 or 4 weeks.
  • the method comprises a single administration to a patient in need thereof, or administration of 0.25 mg/eye, 0.3 mg/eye, 0.6 mg once every week to every 7 weeks, or once every 3 or 4 weeks Aflibercept/eye, 1mg/eye, 1.25mg/eye, 2mg/eye, 2.5mg/eye or 4mg/eye, and 0.5mg/eye, 1mg/eye, 1.5mg/eye or 3mg/eye For non-class.
  • the VEGF antagonist eg, anti-VEGF antibody or antigen-binding fragment, aflibercept (or formulation), batifiban (or formulation) is administered by intravitreal injection.
  • the VEGF antagonist such as anti-VEGF antibody or antigen-binding fragment, aflibercept) (or preparation) is administered by intravitreal injection, and batifiban (or preparation) is administered by dripping Dosing.
  • Figure 1 Changes in retinal thickness in rhesus monkeys after vitreous injection of test substances; among them, Pre-Laser: before modeling, Pre-dose: before administration.
  • Figure 2 Changes in the thickness of the rhesus monkey choroid after vitreous injection of the test substance; among them, Pre-Laser: before modeling, Pre-dose: before administration.
  • Figure 3 Changes in the area of fluorescence leakage in the rhesus monkey fundus after vitreous injection of the test substance; wherein, Pre-dose: before administration.
  • Figure 4 Changes in the intensity of fluorescence leakage in the rhesus monkey fundus after vitreous injection of the test substance; wherein, Pre-dose: before administration.
  • an entity refers to one or more such entities, for example "an antibody” should be understood as one or more antibodies, therefore, the term “a” (or “an” ), “one or more” and “at least one” may be used interchangeably herein.
  • compositions, methods, etc. include the listed elements, such as components or steps, but not exclude others.
  • Consisting essentially of means that the compositions and methods exclude other elements that substantially affect the characteristics of the combination, but do not exclude elements that do not substantially affect the composition or method.
  • Consisting of means excluding elements not specifically recited.
  • polypeptide is intended to encompass the singular as well as the plural “polypeptides” and refers to a molecule composed of amino acid monomers linked linearly by amide bonds (also known as peptide bonds).
  • polypeptide refers to any chain or chains of two or more amino acids, and does not refer to a specific length of the product.
  • the definition of “polypeptide” includes peptide, dipeptide, tripeptide, oligopeptide, "protein”, “amino acid chain” or any other term used to refer to a chain of two or more amino acids, and the term “polypeptide” may Used in place of, or interchangeably with, any of the above terms.
  • polypeptide is also intended to refer to the products of post-expression modifications of the polypeptide, including but not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, or non-natural Amino acid modifications that occur.
  • a polypeptide may be derived from natural biological sources or produced by recombinant techniques, but it need not be translated from a specified nucleic acid sequence, it may be produced by any means including chemical synthesis.
  • amino acid refers to an organic compound containing both amino and carboxyl groups, such as an ⁇ -amino acid, which can be encoded by a nucleic acid directly or in the form of a precursor.
  • a single amino acid is encoded by a nucleic acid consisting of three nucleotides (so-called codons or base triplets). Each amino acid is encoded by at least one codon. The fact that the same amino acid is encoded by different codons is called “degeneracy of the genetic code”.
  • Amino acids include natural amino acids and unnatural amino acids.
  • Natural amino acids include alanine (three-letter code: ala, one-letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine amino acid (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I ), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y) and valine (val, V).
  • a “conservative amino acid substitution” refers to the replacement of one amino acid residue with another amino acid residue containing a side chain (R group) of similar chemical properties (eg, charge or hydrophobicity). In general, conservative amino acid substitutions are unlikely to substantially alter the functional properties of a protein.
  • classes of amino acids that contain chemically similar side chains include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic hydroxyl side chains: serine and threonine 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, Arginine and histidine; 6) acidic side chains: aspartic acid and glutamic acid.
  • the number of amino acids in the "conservative amino acid substitution of VL, VH" can be about 1, about 2, about 3, about 4, about 5, about 6, about 8, about 9, about 10, About 11, about 13, about 14, about 15 conservative amino acid substitutions, or a range between any two of these values (inclusive), or any value therein.
  • the number of amino acids for "conservative amino acid substitutions in the heavy or light chain” can be about 1, about 2, about 3, about 4, about 5, about 6, about 8, about 9, about 10 about 11, about 13, about 14, about 15, about 18, about 19, about 22, about 24, about 25, about 29, about 31, about 35, About 38, about 41, about 45 conservative amino acid substitutions, or a range between any two of these values (inclusive), or any value therein.
  • encoding when applied to a polynucleotide refers to a polynucleotide which is said to "encode” a polypeptide which, in its native state or when manipulated by methods well known to those skilled in the art, is transcribed and/or Or translation may result in the polypeptide and/or fragments thereof.
  • Antibodies, antigen-binding fragments or derivatives disclosed in the present invention include but are not limited to polyclonal, monoclonal, multispecific, fully human, humanized, primatized, chimeric antibodies, single-chain antibodies, antigen-binding fragments (eg Fab, Fab' and F(ab') 2 ), scFv).
  • polypeptides or polynucleotides refers to polypeptides or polynucleotides, meaning forms of polypeptides or polynucleotides that do not occur in nature, non-limiting examples may be produced by combination of polynucleotides or polynucleotides that do not normally exist or peptide.
  • Homology refers to the sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing the alignable positions in each sequence. When a position in the sequences being compared is occupied by the same base or amino acid, then the molecules are homologous at that position. The degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences.
  • At least 80% identity is about 80% identity, about 81% identity, about 82% identity, about 83% identity, about 85% identity, about 86% identity, about 87% identity, About 88% identity, about 90% identity, about 91% identity, about 92% identity, about 94% identity, about 95% identity, about 98% identity, about 99% identity, or these A range (inclusive) between any two values in Numeric or any value therein.
  • a nucleic acid or polynucleotide sequence (or polypeptide or antibody sequence) having a certain percentage (eg, 90%, 95%, 98%, or 99%) of "identity" or "sequence identity” with another sequence means When sequences are aligned, the percentage of bases (or amino acids) in the two sequences being compared are the same. This alignment percent identity or sequence identity can be determined using visual inspection or software programs known in the art, such as those described by Ausubel et al.eds. (2007) in Current Protocols in Molecular Biology. It is preferred to use the default parameters for the alignment.
  • Biologically equivalent polynucleotides are polynucleotides that share the above indicated percentages of identity and encode polypeptides having the same or similar biological activity.
  • Antibody and antigen-binding fragment refer to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen.
  • Antibodies can be whole antibodies and any antigen-binding fragments thereof or single chains thereof.
  • the term “antibody” thus includes any protein or peptide whose molecule contains at least a portion of an immunoglobulin molecule that has the biological activity to bind an antigen.
  • Antibodies and antigen-binding fragments include, but are not limited to, complementarity determining regions (CDRs), heavy chain variable regions (VH), light chain variable regions (VL), heavy chain constant regions of heavy or light chains or ligand-binding portions thereof (CH), light chain constant region (CL), framework region (FR) or any portion thereof, or at least a portion of a binding protein.
  • CDR regions include the CDR regions of the light chain (LCDR1-3) and the CDR regions of the heavy chain (HCDR1-3).
  • antibody includes a wide variety of polypeptides that can be distinguished biochemically.
  • classes of heavy chains include gamma, mu, alpha, delta or epsilon ( ⁇ , ⁇ , ⁇ , ⁇ , ⁇ ), with some subclasses (eg ⁇ 1- ⁇ 4).
  • the nature of this chain determines the "class” of the antibody as IgG, IgM, IgA, IgG or IgE, respectively.
  • the immunoglobulin subclasses (isotypes), eg, IgGl, IgG2, IgG3, IgG4, IgG5, etc., are well characterized and the functional specificities conferred are also known. All immunoglobulin classes are within the scope of the present disclosure. In some embodiments, the immunoglobulin molecule is of the IgG class.
  • Light chains can be classified as kappa ( ⁇ ) or lambda ( ⁇ ). Each heavy chain can be associated with a kappa or lambda light chain.
  • ⁇ kappa
  • lambda ⁇
  • Each heavy chain can be associated with a kappa or lambda light chain.
  • immunoglobulins are produced by hybridomas, B cells, or genetically engineered host cells, their light and heavy chains are joined by covalent bonds, and the "tail" portions of the two heavy chains are linked by covalent disulfide bonds or non-covalent bonding.
  • the amino acid sequence extends from the N-terminus at the forked end of the Y configuration to the C-terminus at the bottom of each chain.
  • the variable region of the immunoglobulin kappa light chain is V ⁇ ; the variable region of the immunoglobulin lambda light chain is V ⁇ .
  • variable and variable are used according to function.
  • the variable region of the light chain (VL) and the variable region of the heavy chain (VH) determine antigen recognition and specificity.
  • the constant region (CL) of the light chain and the constant region (CH) of the heavy chain confer important biological properties such as secretion, transplacental movement, Fc receptor binding, complement fixation, etc.
  • the numbering of constant regions increases as they become farther away from the antigen-binding site or amino terminus of the antibody.
  • the N-terminal portion is the variable region and the C-terminal portion is the constant region; the CH3 and CL domains actually comprise the carboxy-terminal ends of the heavy and light chains, respectively.
  • CDR complementarity determining regions
  • CDRs as defined by Kabat and Chothia include overlapping or subsets of amino acid residues when compared to each other. Nevertheless, it is within the scope of the invention to use either definition to refer to the CDRs of an antibody or variant thereof.
  • the exact residue numbers comprising a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can generally determine which specific residues are included in the CDRs based on the amino acid sequence of the variable region of the antibody.
  • Kabat et al. also defined a numbering system applicable to the variable region sequences of any antibody.
  • One of ordinary skill in the art can apply this "Kabat numbering" system to any variable region sequence independently of other experimental data other than the sequence itself.
  • “Kabat numbering” refers to the numbering system proposed by Kabat et al., U.S. Dept. of Health and Human Services in "Sequence of Proteins of Immunological Interest” (1983).
  • Antibodies can also use the EU or Chothia numbering system.
  • Treatment means therapeutic treatment and prophylactic or preventative measures, the purpose of which is to prevent, slow down, ameliorate and stop undesirable physiological changes or disorders, such as the progression of disease, including but not limited to the following whether detectable or undetectable Relief of symptoms, reduction of disease extent, stabilization of disease state (i.e. not worsening), delay or slowing of disease progression, improvement or palliation of disease state, alleviation or disappearance (whether partial or total), prolongation and Expected survival without treatment, etc.
  • Patients in need of treatment include those who already have a condition or disorder, are susceptible to a condition or disorder, or are in need of prevention of the condition or disorder, and can or are expected to benefit from the administration of an antibody or composition disclosed herein for detection, Patients who benefit from the diagnostic process and/or treatment.
  • Patient refers to any mammal in need of diagnosis, prognosis, or treatment, including humans, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, and the like.
  • Effective amount refers to the amount of an active compound or agent capable of eliciting a biological or medical response in a tissue, system, animal, individual or human.
  • the phrase "in need thereof” means that a patient has been identified as being in need of a particular method or treatment. In some embodiments, identification may be by any diagnostic means.
  • an antibody expression vector includes at least one promoter element, an antibody coding sequence, a transcription termination signal, and a polyA tail.
  • Other elements include enhancers, Kozak sequences, and donor and acceptor sites for RNA splicing flanking the inserted sequence.
  • High-efficiency transcription can be obtained through the early and late promoters of SV40, long terminal repeats from retroviruses such as RSV, HTLV1, HIVI, and early promoters of cytomegalovirus, and other cellular promoters such as muscle Kinetin promoter.
  • Suitable expression vectors may include pIRES1neo, pRetro-Off, pRetro-On, PLXSN, or pLNCX, pcDNA3.1(+/-), pcDNA/Zeo(+/-), pcDNA3.1/Hygro(+/-), PSVL, PMSG, pRSVcat, pSV2dhfr, pBC12MI and pCS2 etc.
  • Commonly used mammalian cells include HEK293 cells, Cos1 cells, Cos7 cells, CV1 cells, mouse L cells and CHO cells, etc.
  • the amino acid sequence of the anti-VEGF antibody (BAT5906) is shown in Table 1.
  • D1-D21 day 1-21
  • AMD model was constructed (Zhaoyan (Suzhou) New Drug Research Center Co., Ltd.), and D22 was selected to have 4-level leakage spots
  • the animals were enrolled in the group, and were averagely grouped according to the average leakage area of the 4th-grade spot and the rate of the 4th-grade spot. The grouping and administration methods are shown in Table 2.
  • Level 1 no hyperfluorescence in the spot
  • level 2 high fluorescence in the spot but no fluorescence leakage
  • level 3 high fluorescence in the spot, slight fluorescence leakage, and the leakage does not exceed the edge of the spot
  • 4 Level high spot fluorescence, severe fluorescence leakage, leakage beyond the edge of the spot.
  • Rhesus monkeys (common grade) were subjected to CNV modeling, and 3 weeks after modeling, they were randomly divided into 5 groups (10 animals, including the vehicle control group) according to the four-level fluorescence leakage, with 2 animals in each group, grouped and administered The method is shown in Table 4, and the day of administration is named Day1 (ie D1). Carry out detailed clinical observations to all animals during the adaptation period, modeling period and experiment period; before modeling, before administration (2 weeks after modeling, D-1), D7, D14 after administration to all surviving experimental animals. Eye irritation test, eye examination, fundus test (fundus photography, OCT and FFA examination).
  • *Batifiban+BAT5906 group, Batifiban+Aflibercept group are two kinds of drug combination, need to be mixed before administration, and then injected into the vitreous of the test eye; vehicle control group, BAT5906
  • the administration volume of the group and the aflibercept group was 50 ⁇ L/eye
  • the administration volume of the batifiban+BAT5906 group and the batifiban+aflibercept group was 100 ⁇ L/eye.
  • both animal #202 and animal #303 had slight turbidity in both corneas on D7, and returned to normal when checked on D14; animal #403 (Aflibercept group) had slight aqueous humor flare in the left eye, which was checked on D14 Return to normal; the left eye of animal #301 (batifiban + BAT5906 group) appeared dark red conjunctival hyperemia, severe corneal turbidity, moderate aqueous humor flashes on D7, unable to observe fundus structures and other inflammatory phenomena, and did not recover until the end of the animal experiment , may be caused by the small eyeball of the animal and the edema of the intraocular tissue caused by the large volume of the vitreous injection preparation (100 ⁇ L); the rest of the animals had no abnormal symptoms during the ophthalmic examination during the administration period.
  • %diff (Day n-Pre-dose)/Pre-dose*100; Pre-dose: before administration; *301 intraocular inflammation occurred in the left eye of the animal after administration, and the follow-up fundus detection data were not available.
  • %diff (Day n-Pre-dose)/Pre-dose*100; pre-dose: before administration; *301 intraocular inflammation occurred in the left eye of the animal after administration, and the follow-up fundus detection data were not available.
  • %diff (Day n-Pre-dose)/Pre-dose*100; Pre-Laser: before modeling; Pre-dose: before administration; *301 intraocular inflammation occurred in the left eye of the animal after administration, Subsequent fundus examination data were not available.
  • %diff (Day n-Pre-dose)/Pre-dose*100; Pre-dose: before administration; *301 intraocular inflammation occurred in the left eye of the animal after administration, and the follow-up fundus detection data were not available.
  • Retinal thickness All groups of animals showed an increase in thickness after modeling, and the restoration of retinal thickness after administration changed from high to low in the order of batyfiban + BAT5906 group, batifiban + aflibyci Common group, BAT5906 group, vehicle control group, aflibercept group. In addition to the self-recovery of the retina with the progress of the test, it shows that the Batifiban+BAT5906 group, the Batifiban+Aflibercept group, and the BAT5906 group have a certain repair function on the retina after administration.
  • Choroidal thickness after administration of animals in each group, the thickness of the choroid showed a certain degree of damage, and the change of choroidal thickness after administration changed from high to low as Batifiban+BAT5906 group, BAT5906 group, BAT5906 group, Batifiban + aflibercept group, vehicle control group, and aflibercept group, among which the batifiban + BAT5906 group had the best repair, followed by the BAT5906 group and the batifiban + aflibercept group, and the vehicle The performance of the control group and the aflibercept group were relatively consistent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了整合素GPIIb/IIIa拮抗剂及其与VEGF拮抗剂联合用药在治疗眼类疾病中的应用，治疗方法包括向有需要的患者给药有效量的整合素GPIIb/IIIa拮抗剂或整合素GPIIb/IIIa拮抗剂和VEGF拮抗剂。

Description

整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 技术领域
本发明属于生物医药领域，尤其涉及整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用。
背景技术
黄斑变性是一种主要在老年人中发现的医学病症，其中已知为视网膜黄斑区域的眼睛的内衬中心变薄、萎缩，并且在一些情形中出血。这可能导致中央视觉的丧失，这使得患者不能看到更详细的内容。根据美国眼科学会的报道，黄斑变性是老年人的中央视觉丧失(失明)的主要原因。尽管一些影响年轻人的黄斑营养不良(macular dystrophies)有时也称为黄斑变性，但是该术语通常是指年龄相关性黄斑变性(age-related maculardegeneration,AMD)。
年龄相关黄斑病变是视网膜色素上皮细胞和神经视网膜退化造成的一种不可逆性视力下降或丧失的疾病。多发生于50岁以上的患者，双眼先后或同时发病，且进行性损害视力，是一种严重威胁老年人视功能的眼底病变。随着人口老龄化，在西方国家已成为第一位的致盲性眼病，在亚洲其发病率亦呈逐渐增多的趋势。
发明内容
本发明公开了整合素GPIIb/IIIa拮抗剂治疗眼类疾病的方法或用途。在一些实施方案中，所述方法或用途包括：向有需要的患者施用有效量的整合素GPIIb/IIIa拮抗剂。另一方面，本发明公开了整合素GPIIb/IIIa拮抗剂在制备用于治疗眼类疾病的药物中的应用。
另一方面，本发明还公开了试剂盒，所述试剂盒包含整合素GPIIb/IIIa拮抗剂(或制剂)，以及用于指导有需要患者给药整合素GPIIb/IIIa拮抗剂(或制剂)的说明书。
在一些实施方案中，眼类疾病为VEGF过表达的眼类疾病如VEGF过表达的眼底病变。在一些实施方案中，眼类疾病选自黄斑变性、年龄相关性黄斑变性(AMD)、角膜新生血管形成、与角膜新生血管形成相关的疾病、视网膜新生血管形成、与视网膜/脉络膜新生血管形成相关的疾病、病理性近视继发脉络膜新生血管、虹膜新生血管形成、眼内新生血管形成、眼新生血管病、新生血管性青光眼、黄斑水肿、糖尿病性黄斑水肿(DME，包括局部、非中心DME和弥散性、包括中心的DME)、囊样黄斑 水肿(CME)、视网膜病、糖尿病性视网膜病变(DR，包括增生性DR(PDR)，非增生性DR(NPDR)，和高海拔DR)、其他缺血相关的视网膜病、早产儿视网膜病(ROP)、家族性渗出性玻璃体视网膜病(FEVR)、高血压视网膜病、视网膜静脉阻塞(RVO)(包括视网膜分枝静脉阻塞和视网膜中央静脉阻塞)、CNV(包括近视CNV)、病理性近视、希佩尔-林道病、冠茨病、诺里病、骨质疏松症-假神经胶质瘤综合征(OPPG)、结膜下出血，发红、色素性视网膜炎(RP)、视网膜血管瘤增生、黄斑毛细管扩张、视网膜变性、血管炎、视盘水肿、视网膜炎、结膜炎(包括传染性结膜炎和非传染性(例如，过敏性)结膜炎)、利伯先天性黑矇、葡萄膜炎(包括传染性和非传染性葡萄膜炎)、脉络膜炎、眼组织胞浆菌病、眼睑炎、干眼、外伤性眼损伤和舍格伦病中的一种或多种。
另一方面，本发明公开了包含整合素GPIIb/IIIa拮抗剂的眼用药物组合物。在一些实施方案中，眼用药物组合物还包括药学上可接受的载体。
在一些实施方案中，整合素GPIIb/IIIa拮抗剂或其药物组合物用于增强VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)治疗眼类疾病如VEGF过表达的眼类疾病的效果中的用途。
另一方面，本发明公开了VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂联合治疗眼类疾病如VEGF过表达的眼类疾病的方法或用途。在一些实施方案中，所述方法或用途包括：向有需要的患者施用有效量的VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂。另一方面，本发明公开了VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂在制备用于治疗眼类疾病如VEGF过表达的眼类疾病的药物中的应用。
另一方面，本发明还公开了试剂盒，所述试剂盒包含VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)(或制剂)、整合素GPIIb/IIIa拮抗剂(或制剂)，以及用于指导有需要患者给药VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)(或制剂)和整合素GPIIb/IIIa拮抗剂(或制剂)的说明书。在一些实施方案中，本发明还公开了试剂盒，所述试剂盒包含VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂的组合物(或制剂)，以及用于指导有需要患者给药VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂的组合物(或制剂)的说明书。
另一方面，本发明还公开了包含VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂的适合注射用的药物组合物。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂的质量比为(0.5-7):1。在一些实施方 案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂的质量比为(1-7):1。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂的质量比为(1-4):1。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂的质量比为1:1。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂的质量比为2:1。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂的质量比为4:1。在一些实施方案中，药物组合物至少包含0.1％的VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和0.1％的整合素GPIIb/IIIa拮抗剂。VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂的百分比可以变化，可以为给定剂型重量的约2％和约90％之间。这种治疗上有用的药物组合物中VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂可以为给药的有效量。
另一方面，本发明还公开了上述药物组合物的制备方法：分别将VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂(或VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂的组合物)与药学上可接受的适合注射用的载体(例如注射用水，生理盐水等)混合。VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂，与药学上可接受的载体的混合方法是本领域通常已知的。
另一方面，本发明还公开了VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和整合素GPIIb/IIIa拮抗剂在制备用于治疗眼类疾病如VEGF过表达的眼类疾病的药物组合物中的用途。
在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)联合整合素GPIIb/IIIa拮抗剂用于治疗眼类疾病如VEGF过表达的眼类疾病。本发明将VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)(或制剂)和整合素GPIIb/IIIa拮抗剂(或制剂)用于眼类疾病如VEGF过表达的眼类疾病的治疗中，可以减缓症状。
在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)(或制剂)、整合素GPIIb/IIIa拮抗剂(或制剂)与其他治疗方法联合用于治疗眼类疾病如VEGF过表达的眼类疾病，例如手术治疗、激光治疗、物理康复和药物治疗(如阿柏西普
Figure PCTCN2022107388-appb-000001
康柏西普
Figure PCTCN2022107388-appb-000002
)等。
在一些实施方案中，VEGF拮抗剂为抗VEGF抗体或抗原结合片段。
在一些实施方案中，所述抗VEGF抗体或抗原结合片段至少包含SEQ ID NO:1所示的HCDR1、SEQ ID NO:2所示的HCDR2、SEQ ID NO:3所示的HCDR3、SEQ ID NO:4所示的LCDR1、SEQ ID NO:5所示的LCDR2、SEQ ID NO:6所示的LCDR3中一个或 多个。
在一些实施方案中，所述抗VEGF抗体或抗原结合片段包含SEQ ID NO:1所示的HCDR1、SEQ ID NO:2所示的HCDR2、SEQ ID NO:3所示的HCDR3、SEQ ID NO:4所示的LCDR1、SEQ ID NO:5所示的LCDR2和SEQ ID NO:6所示的LCDR3。
在一些实施方案中，所述抗VEGF抗体或抗原结合片段的重链可变区包含SEQ ID NO:7所示的序列，或与SEQ ID NO:7所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:7所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列；和/或
所述抗VEGF抗体或抗原结合片段的轻链可变区包含SEQ ID NO:8所示的序列，或与SEQ ID NO:8所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:8所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列。
在一些实施方案中，所述抗VEGF抗体或抗原结合片段的重链可变区包含SEQ ID NO:7所示的序列，所述抗VEGF抗体或抗原结合片段的轻链可变区包含SEQ ID NO:8所示的序列。
在一些实施方案中，所述抗VEGF抗体的重链包含SEQ ID NO:9所示的序列，或与SEQ ID NO:9所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:9所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列；和/或
所述抗VEGF抗体的轻链包含SEQ ID NO:10所示的序列，或与SEQ ID NO:10所示序列具有至少80％同一性的序列，或与SEQ ID NO:10所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列。
在一些实施方案中，所述抗VEGF抗体的重链包含SEQ ID NO:9所示的序列，所述抗VEGF抗体的轻链包含SEQ ID NO:10所示的序列。
在一些实施方案中，VEGF拮抗剂选自抗VEGF抗体或抗原结合片段、抗VEGF受体抗体或抗原结合片段、VEGF受体融合蛋白、与VEGF特异性结合的适体和VEGFR酪氨酸激酶抑制剂。在一些实施方案中，所述抗VEGF抗体为布洛赛珠单抗、贝伐珠单抗、雷珠单抗或ZL201910585853.9公开的单克隆抗体BAT5906。在一些实施方案中，贝伐珠单抗包括
Figure PCTCN2022107388-appb-000003
或其生物类似物，如
Figure PCTCN2022107388-appb-000004
普贝希、朴欣汀、贝安汀、艾瑞妥、博优诺、或BAT1706。在一些实施方案中，雷珠单抗包括
Figure PCTCN2022107388-appb-000005
或其生物类似物。在一些实施方案中，VEGF受体融合蛋白选自阿柏西普
Figure PCTCN2022107388-appb-000006
和康柏西普。在一些实施方案中，与VEGF特异性结合的适体为培加尼布
Figure PCTCN2022107388-appb-000007
在一些实施方案中，VEGFR酪氨酸激酶抑制剂选自：4-(4-溴-2-氟苯胺基)-6-甲氧基-7-(1-甲基哌啶-4-基甲氧基)喹唑啉(ZD6474)、4-(4-氟-2-甲基吲哚-5-基氧基)-6-甲氧基-7-(3-吡咯烷-1-基丙氧基)喹唑啉(AZD2171)、伐他拉尼 (PTK787)、semaxaminib(SU5416)和舒尼替尼
Figure PCTCN2022107388-appb-000008
在一些实施方案中，VEGF拮抗剂蛋白可以通过基因工程在细胞如CHO细胞或HEK293细胞中表达，并通过纯化获得；纯化可以采用常规方法进行，例如离心细胞悬液并收集上清液。亲和柱和离子交换柱等方法可以用于进一步纯化VEGF拮抗剂蛋白。
在一些实施方案中，所述整合素GPIIb/IIIa拮抗剂为巴替非班(ZL03112798.3公开的XP2094)或其药学上可接受的盐。在一些实施方案中，所述巴替非班药学上可接受盐为无机酸盐，无机酸可以是：次碘酸、次氯酸、次溴酸、碘酸、高氯酸、过二硫酸、过二碳酸、过碳酸、焦磷酸、焦硫酸、焦亚硫酸、连四硫酸、磷酸、硫代硫酸、硫酸、氯酸、偏磷酸、氢碘酸、氢叠氮酸、氢氟酸、氢硫酸、氢氯酸、氢溴酸、四硼酸、碳酸、硝酸、溴酸、亚硫酸、亚磷酸、亚氯酸、盐酸、亚硝酸、原磷酸、原硫酸、原碳酸等无机酸。在一些实施方案中，所述巴替非班药学上可接受盐为有机酸盐，有机酸可以是：酒石酸、草酸、苹果酸、枸橼酸(柠檬酸)、抗坏血酸、苯甲酸、水杨酸、咖啡酸、乳酸、山梨酸、延胡索酸、甲酸、乙酸、苯甲酸、乙二酸、丁二酸、丙酮酸、α-酮丁二酸、苯磺酸、或三氟乙酸、马来酸、四磺酸、甲磺酸、富马酸、氨基酸等。在一些实施方案中，所述有机酸为枸橼酸(柠檬酸)、苹果酸、乳酸、乙酸、乙二酸、氨基酸。在一些实施方案中，所述巴替非班药学上可接受盐为枸橼酸盐。在一些实施方案中，所述巴替非班药学上可接受盐为巴替非班与金属离子(例如，碱金属离子(如钠或钾)、碱土金属离子(例如钙或镁)或铝离子)或者与有机碱(如二乙醇胺、三乙醇胺、N-甲基葡糖胺)等形成的盐。
在一些实施方案中，本发明公开了一种用于治疗有需要患者的眼类疾病如VEGF过表达的眼类疾病的方法，其包括施用有效量的VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班或其药学可接受的盐，其中VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)施用的有效量为约0.1mg至15mg每个治疗周期。在一些实施方案中，一个治疗周期为1周、2周、3周、4周、1个月、5周、6周、7周，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体或抗原结合片段。在一些实施方案中，所述抗VEGF抗体为抗体BAT5906。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，可以分别将VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)和巴替非班或其药学可接受的盐(或VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班或其药学可接受的盐的组合物)配制成药物组合物，并以适合于所选给药途径的多种形式向患者给药， 例如通过眼局部外用、眼周注射或眼球内注射等方式进行给药。在一些实施方案中，可以将VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)(或制剂)通过玻璃体注射方式进行给药，巴替非班或其药学可接受的盐(或制剂)通过滴入结膜囊方式进行给药。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班或其药学可接受的盐的组合物通过玻璃体注射进行给药。VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班或其药学可接受的盐的剂量将取决于药物的性质，细胞表面触发药物的内在化，运输和释放的程度，所治疗的疾病，患者的状况(如年龄，性别，体重等)。
在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂剂量的质量比为(0.5-7):1。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂剂量的质量比为(1-7):1。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂剂量的质量比为(1-4):1。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂剂量的质量比为1:1。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂剂量的质量比为2:1。在一些实施方案中，VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂剂量的质量比为4:1。
在一些实施方案中，每次施用的VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)约0.1mg/眼至7.5mg/眼或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂。含VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂可以为适于注射用途的制剂包括无菌水性溶液(在此是水溶性的)或分散体以及用于即时制备无菌注射液或分散体的无菌粉末。对于眼内注射用，合适的载体包括生理盐水或抑菌水等。在一些实施方案中，制剂至少包含0.1％的VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)。抗体的百分比可以变化，并且为给定剂型重量可以约2％至90％之间。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，每次施用的VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)为约0.1mg/眼、约0.2mg/眼、约0.3mg/眼、约0.5mg/眼、约0.9mg/眼、约1mg/眼、约1.25mg/眼、约2mg/眼、约2.5mg/眼、约3mg/眼、约4mg/眼、约5mg/眼、约6mg/眼、约7.5mg/眼，或这些数值中任何两个值之间的范围(包括端点)或其中任何值，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)施用的有效剂量为每剂约0.1mg至15mg。在一些实施方 案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)施用的有效剂量为每剂约0.1mg至8mg。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)施用的有效剂量为每剂约8mg至15mg。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体(如抗体BAT5906)或抗原结合片段、阿柏西普)施用的有效量为0.1mg至15mg每2周、3周、4周、5周或6周一次。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)施用的有效量为约0.1mg、约0.2mg、约0.3mg、约0.4mg、约0.6mg、约1mg、约1.25mg、约2mg、约2.5mg、约3mg、约4mg、约4.5mg、约5mg、约6mg、约7mg、约8mg、约9mg、约10mg、约11mg、约12mg、约13mg、约14mg、约15mg(或这些数值中任何两个值之间的范围(包括端点)或其中任何值)每2周、3周、4周、5周或6周一次。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)施用的有效量为约0.2mg、约0.3mg、约0.6mg、约1mg、约1.25mg、约2mg、约2.5mg、约4mg、约5mg或约8mg每3周、4周或5周一次。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)施用的有效量为约9mg、约10mg、约11mg、12mg、约13mg、约14mg、约15mg每3周、4周或5周一次。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，抗体BAT5906施用的有效量为约1-5mg/眼每4周一次。在一些实施方案中，抗体BAT5906施用的有效量为约1mg/眼、约1.25mg/眼、约2mg/眼、约2.5mg/眼或约4mg/眼每4周一次。
在一些实施方案中，采用治疗有效量的巴替非班或其药学可接受的盐以及VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)分别或者同时施加在患者上。巴替非班或其药学可接受的盐以及VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的给药周期可以相同或者不同。VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班或其药学可接受的盐可以通过相同或者不同方式进行给药。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，抗VEGF抗体或抗原结合片段是通过玻璃体注射方式进行给药。在一些实施方案中，阿柏西普是通过玻璃体注射方式进行给药。在一些实施方案中，巴替非班或其药学可接受的盐是通过滴入结膜囊方式进行给药。在一些实施方案中，巴替非班或其药学可接受的盐是通过玻璃体注射方式进行给药。
在一些实施方案中，所述VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)和巴替非班或其药学可接受的盐分别为独立的给药单元， 联合用药。在一些实施方案中，所述VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)可以在施加巴替非班或其药学可接受的盐之前给药，也可以在施加巴替非班或其药学可接受的盐之后给药，也可以与巴替非班或其药学可接受的盐剂同时给药。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，所述VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)和巴替非班或其药学可接受的盐同时形成组合给药单元，联合用药。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班或其药学可接受的盐的组合物通过玻璃体注射方式进行给药。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，VEGF过表达的眼类疾病为VEGF过表达的眼底病变。在一些实施方案中，VEGF过表达的眼类疾病选自黄斑变性、年龄相关性黄斑变性(AMD)、角膜新生血管形成、与角膜新生血管形成相关的疾病、视网膜新生血管形成、与视网膜/脉络膜新生血管形成相关的疾病、病理性近视继发脉络膜新生血管、虹膜新生血管形成、眼内新生血管形成、眼新生血管病、新生血管性青光眼、黄斑水肿、糖尿病性黄斑水肿(DME，包括局部、非中心DME和弥散性、包括中心的DME)、囊样黄斑水肿(CME)、视网膜病、糖尿病性视网膜病变(DR，包括增生性DR(PDR)，非增生性DR(NPDR)，和高海拔DR)、其他缺血相关的视网膜病、早产儿视网膜病(ROP)、家族性渗出性玻璃体视网膜病(FEVR)、高血压视网膜病、视网膜静脉阻塞(RVO)(包括视网膜分枝静脉阻塞和视网膜中央静脉阻塞)、CNV(包括近视CNV)、病理性近视、希佩尔-林道病、冠茨病、诺里病、骨质疏松症-假神经胶质瘤综合征(OPPG)、结膜下出血，发红、色素性视网膜炎(RP)、视网膜血管瘤增生、黄斑毛细管扩张、视网膜变性、血管炎、视盘水肿、视网膜炎、结膜炎(包括传染性结膜炎和非传染性(例如，过敏性)结膜炎)、利伯先天性黑矇、葡萄膜炎(包括传染性和非传染性葡萄膜炎)、脉络膜炎、眼组织胞浆菌病、眼睑炎、干眼、外伤性眼损伤和舍格伦病中的一种或多种。
在一些实施方案中，巴替非班或其药学可接受的盐施用的有效量为约0.1mg至6mg每个治疗周期。在一些实施方案中，一个治疗周期为1周、2周、3周、4周、1个月、5周、6周、7周，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值。在一些实施方案中，巴替非班或其药学可接受的盐施用的有效量为约0.1mg至3mg每3周、4周或5周1次。在一些实施方案中，巴替非班或其药学可接受的盐施用的有效量为约0.1mg、约0.2mg、约0.3mg、约0.4mg、约0.6mg、约1mg、约1.25mg、约1.5mg、约2mg、约2.5mg、约3mg(或这些数值中的任何两个值之间 的范围(包括端点)或其中任何值)每3周、每4周或每5周1次。在一些实施方案中，巴替非班或其药学可接受的盐施用的有效量为约3mg至约6mg每3周、4周或5周一次。在一些实施方案中，巴替非班或其药学可接受的盐施用的有效量为约3.1mg、约3.5mg、约4mg、约4.6mg、约5mg、约5.3mg、约6mg(或这些数值中的任何两个值之间的范围(包括端点)或其中任何值)每3周、4周或5周一次。
在一些实施方案中，本发明公开了一种治疗眼类疾病如VEGF过表达的眼类疾病的方法，其包括向有需要的患者施用有效量的VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)(或制剂)和巴替非班(或制剂)；其中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为单次给药约0.1mg/眼至7.5mg/眼(或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂)。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，巴替非班的有效量为单次给药约0.1mg/眼至3mg/眼(或含此剂量巴替非班的制剂)。剂量时间表和给药方式取决于某些患者群中的巴替非班(或制剂)、VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)(或制剂)的获益风险评估和一般临床实践指南。
在一些实施方案中，患者每个治疗周期内VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)施用的有效量为约0.1mg至15mg(或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂)，患者每个治疗周期内巴替非班施用的有效量为约0.1mg至6mg(或含此剂量巴替非班的制剂)。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)的有效量是约0.1mg、约0.2mg、约0.3mg、约0.4mg、约0.6mg、约0.8mg、约1mg、约1.2mg、约1.25mg、约2mg、约2.5mg、约3mg、约4mg、约5mg、约6mg、约7mg、约8mg、约9mg、约10mg、约11mg、约12mg、约13mg、约14mg、约15mg，或这些数值中任何两个值之间的范围(包括端点)或其中任何值，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂。在一些实施方案中，一个治疗周期为1周至7周给药1次。在一些实施方案中，每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量是约0.1mg至8mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约1周、约2周、约3周、约4周、约5周、约6周、约7周，或这些数值中的 任何两个值之间的范围(包括端点)或其中任何值。在一些实施方案中，一个治疗周期为约2周、约3周、约4周或约5周。在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约8mg至约15mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约1周、约2周、约3周、约4周、约5周、约6周、约7周，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值。在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约0.2mg、约0.3mg、约0.4mg、约0.6mg、约1mg、约1.25mg、约2mg、约2.5mg、约3mg、约4mg、约5mg、约6mg、约7mg、约8mg、约9mg、约10mg、约11mg、约12mg、约14mg、约15mg，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约2周、约3周、约4周、约5周或约6周。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)的有效量为约0.2mg至0.9mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；比如约0.6mg(0.3mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约0.6mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约3周、约4周或约5周。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)的有效量为约1mg至1.3mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；比如约1.2mg(0.6mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约1.2mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约3周、约4周或约5周。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体 (例如抗体BAT5906)或抗原结合片段、阿柏西普)的有效量为约1.5mg至3mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；比如约2mg(1mg/眼)或约2.5mg(1.25mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约2mg或约2.5mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约3周、约4周或约5周。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)的有效量为约3mg至6mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；比如约4mg(2mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约4mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约3周、约4周或约5周。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)的有效量为约6mg至9mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；比如约8mg(4mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约8mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约3周、约4周或约5周。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)的有效量为约9mg至11mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；比如约10mg(5mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约10mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约3周、约4周或约5周。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿 柏西普。
在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)的有效量为约13mg至15.2mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；比如约15mg(7.5mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约15mg，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的制剂；其中，一个治疗周期为约3周、约4周或约5周。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体(例如抗体BAT5906)或抗原结合片段、阿柏西普)的有效量为约0.1mg至15mg每4周一次。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约0.1mg、约0.2mg、约0.3mg、约0.4mg、约0.6mg、约1mg、约1.25mg、约2mg、约2.5mg、约3mg、约4mg、约5mg、约160mg、约6mg、约7mg、约8mg、约9mg、约10mg、约11mg、约12mg、约14mg、约15mg每3周或4周一次。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约0.1mg/眼、约0.15mg/眼、约0.2mg/眼、约0.3mg/眼、约0.5mg/眼、约0.6mg/眼、约1mg/眼、约1.25mg/眼、约1.5mg/眼、约2mg/眼、约2.5mg/眼、约3mg/眼、约3.5mg/眼、约4mg/眼、约4.5mg/眼、约5mg/眼、约5.5mg/眼、约6mg/眼、约7mg/眼、约7.5mg/眼每3周或4周一次。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)的有效量为约0.2mg/眼、约0.3mg/眼、约0.5mg/眼、约0.6mg/眼、约1mg/眼、约1.25mg/眼、约1.5mg/眼、约2mg/眼、约2.5mg/眼、约3mg/眼、约3.5mg/眼、约4mg/眼每4周一次。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约0.1mg、约0.2mg、约0.3mg、约0.4mg、约0.6mg、约1mg、约1.25mg、约1.5mg、约2mg、约2.5mg、约3mg、约4mg、约5mg、约6mg，或这些数值中任何两个值之间的范围(包括端点)或其中任何值，或含此剂量巴替非班的制剂。在一些实施方案中，一个治疗周期为1周至7周给药1次。在一些实施方案中，每个治疗周期内施用巴替非班的有效量为约0.1mg至3mg，或含此剂量巴替非班的制剂；其中，一个治疗周期为约1约3周、约4周、约5周、约6周、约7周，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值。在一些实施方案中，一个治疗周期为约3周、约4 周或约5周。在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约3mg至约6mg，或含此剂量巴替非班的制剂；其中，一个治疗周期为约3周、约4周或约5周。在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约0.2mg、约0.3mg、约0.4mg、约0.6mg、约1mg、约1.25mg、约1.5mg、约2mg、约2.5mg、约3mg，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值，或含此剂量巴替非班的制剂；其中，一个治疗周期为约3周、约4周或约5周。
在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约0.1mg至0.22mg，或含此剂量巴替非班的制剂；比如约0.2mg(0.1mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约0.2mg，或含此剂量巴替非班的制剂；其中，一个治疗周期为约3周、约4周或约5周。
在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约0.2mg至0.38mg，或含此剂量巴替非班的制剂；比如约0.3mg(0.15mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约0.3mg，或含此剂量巴替非班的制剂；其中，一个治疗周期为约3周、约4周或4周。
在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约0.3mg至0.5mg，或含此剂量巴替非班的制剂；比如约0.4mg(0.2mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约0.4mg，或含此剂量巴替非班的制剂；其中，一个治疗周期为约3周、约4周或约5周。
在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约1mg至1.4mg，或含此剂量巴替非班的制剂；比如约1.2mg(0.6mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约1.2mg，或含此剂量巴替非班的制剂；其中，一个治疗周期为约3周、约4周或约5周。
在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约1.6mg至2.1mg，或含此剂量巴替非班的制剂；比如约2mg(1mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约2mg，或含此剂量巴替非班的制剂；其中，一个治疗周期为约3周、约4周或约5周。
在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约2.2mg至3mg，或含此剂量巴替非班的制剂；比如约2.5mg(1.25mg/眼)给药1次。在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约2.5mg，或含此剂量巴替非班的制剂；其中，一个治疗周期为约3周、约4周或约5周。
在一些实施方案中，患者每个治疗周期内施用巴替非班的有效量为约2.4mg至4mg，或含此剂量巴替非班的制剂；比如约3mg(1.5mg/眼)给药1次。在一些实施方 案中，患者每个治疗周期内施用巴替非班的有效量为约3mg，或含此剂量巴替非班的制剂；其中，一个治疗周期为约3周、约4周或约5周。
在一些实施方案中，患者每个治疗周期内分别给药一次VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班(或给药一次VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班的组合物)。在一些实施方案中，每个治疗周期内多次分别给药VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班(或VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班的组合物)，例如2次、3次、4次或5次。在一些实施方案中，患者每个治疗周期只能给药1次、2次、3次、4次、5次或6次。在一些实施方案中，VEGF拮抗剂为抗VEGF抗体(例如抗体BAT5906)或抗原结合片段。在一些实施方案中，VEGF拮抗剂为阿柏西普。
上述“给药一次或多次”是相对于患者每只眼睛而言。在一些实施方案中，患者双眼均患有VEGF过表达的眼类疾病，“给药1次”是指双眼均需给药1次。在一些实施方案中，患者仅单眼患有与VEGF相关的眼类疾病，给药1次是指单眼给药1次。
在一些实施方案中，患者接受一个治疗周期治疗。在一些实施方案中，患者接受多个(例如2个、3个、3个、4个、5个、6个、7个、8个、9个、10个、11个、12次、13个、14个、15个、16个或17个)治疗周期治疗。在一些实施方案中，患者接受治疗直至病症得到缓解而不再需要治疗。
在一些实施方案中，本发明公开了一种用于治疗VEGF过表达的眼类疾病的方法，所述方法包括：向有需要的患者给予约0.1mg/眼至1.25mg/眼、约1.25mg/眼至2.5mg/眼、约2.5mg/眼至4mg/眼、约4mg/眼至6mg/眼、约6mg/眼至7.5mg/眼，比如约0.1mg/眼、0.2mg/眼、0.3mg/眼、0.4mg/眼、0.5mg/眼、0.6mg/眼、0.8mg/眼、1mg/眼、1.25mg/眼、1.3mg/眼、2mg/眼、2.5mg/眼、3mg/眼、4mg/眼、5mg/眼、6mg/眼、7.5mg/眼的VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)，或含此剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段的制剂、阿柏西普)；还向有需要的患者给予约0.1mg/眼至1.25mg/眼、约1.25mg/眼至2.5mg/眼、约2.5mg/眼至3mg/眼，比如约0.1mg/眼、0.2mg/眼、0.3mg/眼、0.4mg/眼、0.5mg/眼、0.6mg/眼、0.8mg/眼、1mg/眼、1.25mg/眼、1.3mg/眼、2mg/眼、2.5mg/眼、3mg/眼的巴替非班，或含此剂量巴替非班的制剂。在一些实施方案中，患者接受单剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班的治疗。在一些实施方案中，患者接受单剂量VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和巴替非班组合物的治疗。
在一些实施方案中，每3周或4周一次给药VEGF拮抗剂(例如抗VEGF抗体或 抗原结合片段、阿柏西普)和巴替非班。
在一些实施方案中，单剂量给药后，患者的症状得到缓解。在一些实施方案中，单剂量给药后，患者后的症状未得到预期缓解，再对患者分别或同时给药约0.1mg/眼至7.5mg/眼VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)和约0.1mg/眼至3mg/眼巴替非班。
在一些实施方案中，抗VEGF抗体为抗体BAT5906。
在一些实施方案中，本发明公开了一种用于治疗VEGF过表达的眼类疾病的方法，所述方法包括向有需要的患者单次给药、或每周至每7周一次给予、或每3周或4周一次给予0.1mg/眼至7.5mg/眼的抗体BAT5906和0.1mg/眼到3mg/眼的巴替非班。在一些实施方案中，所述方法包括向有需要的患者单次给药、或每周至每7周一次给予、或每3周或4周一次给予0.25mg/眼、0.3mg/眼、0.6mg/眼、1mg/眼、1.25mg/眼、2mg/眼、2.5mg/眼或4mg/眼的抗体BAT5906，以及1mg/眼或0.5mg/眼的巴替非班。在一些实施方案中，所述方法包括向有需要的患者单次给药、或每周至每7周一次给予、或每3周或4周一次给予0.25mg/眼、0.3mg/眼、0.6mg/眼、1mg/眼、1.25mg/眼、2mg/眼、2.5mg/眼或4mg/眼的抗体BAT5906，以及1.5mg/眼或3mg/眼的巴替非班。
在一些实施方案中，本发明公开了一种用于治疗VEGF过表达的眼类疾病的方法，所述方法包括向有需要的患者单次给药、或每周至每7周一次给予、或每3周或4周一次给予0.1mg/眼至7.5mg/眼的阿柏西普和0.1mg/眼到3mg/眼的巴替非班。在一些实施方案中，所述方法包括向有需要的患者单次给药、或每周至每7周一次给予、或每3周或4周一次给予0.25mg/眼、0.3mg/眼、0.6mg/眼、1mg/眼、1.25mg/眼、2mg/眼、2.5mg/眼或4mg/眼的阿柏西普，以及0.5mg/眼、1mg/眼、1.5mg/眼或3mg/眼的巴替非班。
在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)(或制剂)、巴替非班(或制剂)是通过玻璃体注射方式进行给药。在一些实施方案中，VEGF拮抗剂(例如抗VEGF抗体或抗原结合片段、阿柏西普)(或制剂)是通过玻璃体注射方式进行给药，巴替非班(或制剂)是通过滴药方式进行给药。
附图说明
图1：玻璃体注射给予受试物后恒河猴视网膜厚度变化；其中，Pre-Laser：造模前，Pre-dose：给药前。
图2：玻璃体注射给予受试物后恒河猴脉络膜厚度变化；其中，Pre-Laser：造模前，Pre-dose：给药前。
图3：玻璃体注射给予受试物后恒河猴眼底荧光渗漏面积变化；其中，Pre-dose：给药前。
图4：玻璃体注射给予受试物后恒河猴眼底荧光渗漏强度变化；其中，Pre-dose：给药前。
术语
除非另作说明，否则下列的每一个术语应当具有下文所述的含义。
定义
应当注意的是，术语“一种”实体是指一种或多种该实体，例如“一种抗体”应当被理解为一种或多种抗体，因此，术语“一种”(或“一个”)、“一种或多种”和“至少一种”可以在本文中互换使用。
本文所用的术语“包含”或“包括”意味着组合物和方法等包括所列举的元素，例如组份或步骤，但不排除其它。“基本上由……组成”意味着组合物和方法排除对组合的特征有根本影响的其它元素，但不排除对组合物或方法无本质上影响的元素。“由……组成”意味着排除未特别列举的元素。
术语“多肽”旨在涵盖单数的“多肽”以及复数的“多肽”，并且是指由通过酰胺键(也称为肽键)线性连接的氨基酸单体构成的分子。术语“多肽”是指两个或更多个氨基酸的任何单条链或多条链，并且不涉及产物的特定长度。因此，“多肽”的定义中包括肽、二肽、三肽、寡肽、“蛋白质”、“氨基酸链”或用于指两个或多个氨基酸链的任何其他术语，并且术语“多肽”可以用来代替上述任何一个术语，或者与上述任何一个术语交替使用。术语“多肽”也意在指多肽表达后修饰的产物，包括但不限于糖基化、乙酰化、磷酸化、酰胺化、通过已知的保护/封闭基团衍生化、蛋白水解切割或非天然发生的氨基酸修饰。多肽可以源自天然生物来源或通过重组技术产生，但其不必从指定的核酸序列翻译所得，它可能以包括化学合成的任何方式产生。
“氨基酸”是指既含氨基又含羧基的有机化合物，比如α-氨基酸，其可直接或以前体的形式由核酸编码。单个氨基酸由三个核苷酸(所谓的密码子或碱基三联体)组成的核酸编码。每一个氨基酸由至少一个密码子编码。相同氨基酸由不同密码子编码称为“遗传密码的简并性”。氨基酸包括天然氨基酸和非天然氨基酸。天然氨基酸包括丙氨酸(三字母代码：ala，一字母代码：A)、精氨酸(arg，R)、天冬酰胺(asn，N)、天冬氨酸(asp，D)、半胱氨酸(cys，C)、谷氨酰胺(gln，Q)、谷氨酸(glu，E)、甘氨酸(gly，G)、组氨酸(his，H)、异亮氨酸(ile，I)、亮氨酸(leu，L)、赖氨酸(lys，K)、甲硫氨酸(met，M)、苯丙氨酸(phe，F)、脯氨酸(pro，P)、丝氨酸(ser，S)、苏氨酸(thr，T)、色氨酸(trp，W)、酪氨酸(tyr，Y)和缬氨酸(val，V)。
“保守氨基酸取代”是指一个氨基酸残基被另一个含有化学性质(例如电荷或疏水性)相似的侧链(R基团)的氨基酸残基所取代。一般而言，保守氨基酸取代不大会在实质上改变蛋白质的功能性质。含有化学性质相似侧链的氨基酸类别的实例包括：1)脂族侧链：甘氨酸、丙氨酸、缬氨酸、亮氨酸和异亮氨酸；2)脂族羟基侧链：丝氨酸和苏氨酸；3)含酰胺的侧链：天冬酰胺和谷氨酰胺；4)芳族侧链：苯丙氨酸、酪氨酸和色氨酸；5)碱性侧链：赖氨酸、精氨酸和组氨酸；6)酸性侧链：天冬氨酸和谷氨酸。
“VL、VH的保守氨基酸取代”的氨基酸数目可为约1个、约2个、约3个、约4个、约5个、约6个、约8个、约9个、约10个、约11个、约13个、约14个、约15个保守氨基酸取代，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值。“重链或轻链的保守氨基酸取代”的氨基酸数目可为约1个、约2个、约3个、约4个、约5个、约6个、约8个、约9个、约10个、约11个、约13个、约14个、约15个、约18个、约19个、约22个、约24个、约25个、约29个、约31个、约35个、约38个、约41个、约45个保守氨基酸取代，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值。
术语“编码”应用于多聚核苷酸时，是指被称为“编码”多肽的多聚核苷酸，在其天然状态或当通过本领域技术人员公知的方法操作时，经转录和/或翻译可以产生该多肽和/或其片段。
本发明公开的抗体、抗原结合片段或衍生物包括但不限于多克隆、单克隆、多特异性、全人源、人源化、灵长类化、嵌合抗体、单链抗体、抗原结合片段(例如Fab、Fab'和F(ab') 2)、scFv)。
术语“重组”涉及多肽或多聚核苷酸，意指天然不存在的多肽或多聚核苷酸的形式，不受限制的实施例可以通过组合产生通常并不存在的多聚核苷酸或多肽。
“同源性”或“同一性”或“相似性”是指两个肽之间或两个核酸分子之间的序列相似性。可以通过比较每个序列中可以比对的位置来确定同源性。当被比较的序列中的位置被相同的碱基或氨基酸占据时，则分子在该位置是同源的。序列之间的同源程度是由序列共有的匹配或同源位置的数目组成的一个函数。
“至少80％同一性”为约80％同一性、约81％同一性、约82％同一性、约83％同一性、约85％同一性、约86％同一性、约87％同一性、约88％同一性、约90％同一性、约91％同一性、约92％同一性、约94％同一性、约95％同一性、约98％同一性、约99％同一性，或这些数值中的任何两个值之间的范围(包括端点)或其中任何值。
核酸或多聚核苷酸序列(或多肽或抗体序列)与另一序列有具有一定百分比(例 如90％、95％、98％或者99％)的“同一性”或“序列同一性”是指当序列比对时，所比较的两个序列中该百分比的碱基(或氨基酸)相同。可以使用目测或本领域已知的软件程序来确定该比对同一性百分比或序列同一性，比如Ausubel et al.eds.(2007)在Current Protocols in MolecularBiology中所述的软件程序。优选使用默认参数进行比对。其中一种比对程序是使用默认参数的BLAST，例如BLASTN和BLASTP，两者使用下列默认参数：Geneticcode＝standard；filter＝none；strand＝both；cutoff＝60；expect＝10；Matrix＝BLOSUM62；Descriptions＝50sequences；sortby＝HIGHSCORE；Databases＝non-redundant；GenBank+EMBL+DDBJ+PDB+GenBankCDStranslations+SwissProtein+SPupdate+PIR。生物学上等同的多聚核苷酸是具有上述指定百分比的同一性并编码具有相同或相似生物学活性的多肽的多聚核苷酸。
“抗体”、“抗原结合片段”是指特异性识别和结合抗原的多肽或多肽复合物。抗体可以是完整的抗体及其任何抗原结合片段或其单链。因此术语“抗体”包括分子中含有具有与抗原结合的生物学活性的免疫球蛋白分子的至少一部分的任何蛋白质或肽。抗体和抗原结合片段包括但不局限重链或轻链或其配体结合部分的互补决定区(CDR)、重链可变区(VH)、轻链可变区(VL)、重链恒定区(CH)、轻链恒定区(CL)、框架区(FR)或其任何部分，或结合蛋白的至少一部分。CDR区包括轻链的CDR区(LCDR1-3)和重链的CDR区(HCDR1-3)。
术语“抗体”包括可以在生物化学上区分的各种广泛种类的多肽。本领域技术人员将会理解，重链的类别包括gamma、mu、alpha、delta或epsilon(γ、μ、α、δ、ε)，其中还有一些亚类(例如γ1-γ4)。该链的性质决定了抗体的“种类”分别为IgG、IgM、IgA、IgG或IgE。免疫球蛋白亚类(同种型)，例如IgG1、IgG2、IgG3、IgG4、IgG5等已被充分表征并且赋予的功能特异性也已知。所有的免疫球蛋白种类都在本发明公开的保护范围内。在一些实施方案中，免疫球蛋白分子为IgG种类。
轻链可以分为kappa(κ)或lambda(λ)。每个重链可以与κ或λ轻链结合。一般来说，当由杂交瘤，B细胞或基因工程宿主细胞生产免疫球蛋白时，其轻链和重链通过共价键结合，两条重链的“尾巴”部分通过共价二硫键或非共价键结合。在重链中，氨基酸序列从Y构型的叉状末端的N末端延伸至每条链底部的C末端。免疫球蛋白κ轻链可变区为Vκ；免疫球蛋白λ轻链可变区为V λ。
术语“恒定的”和“可变的”根据功能被使用。轻链可变区(VL)和重链可变区(VH)决定了抗原识别和特异性。轻链的恒定区(CL)和重链的恒定区(CH)赋予重要的生物学性质，如分泌、经胎盘移动、Fc受体结合、补体结合等。按照惯例，恒定区的编号随着它们变得更远离抗体的抗原结合位点或氨基末端而增加。N端部分是可变区，C端部分是恒定区；CH3和CL结构域实际上分别包含重链和轻链的羧基端。
在本领域中使用和/或接受的术语有两个或多个定义的情况下，除非明确地对立指出，否则本文使用的术语的定义包括所有这些含义。一个具体的例子是使用“互补决定区”(“CDR”)一词来描述在重链和轻链多肽的可变区内发现的非连续的抗原结合位点。这一特定区域在Kabat et al.,U.S.Dept.of Health and Human Services,Sequences of Proteins of Immunological Interest(1983)和Chothia等在J.Mol.Biol.196:901-917(1987)有相关描述，其通过引用全部并入本文。
根据Kabat和Chothia定义的CDR包括相互比较时的氨基酸残基的重叠或子集。尽管如此，应用任一定义来指代抗体或其变体的CDR都在本发明范围内。包含特定CDR的确切残基编号将根据CDR的序列和大小而变化。本领域技术人员通常可以根据抗体的可变区氨基酸序列确定出CDR包含哪些特定的残基。
Kabat等人还定义了适用于任何抗体的可变区序列的编号系统。本领域普通技术人员可以不依赖于序列本身以外的其他实验数据将该“Kabat编号”系统应用到任何可变区序列。“Kabat编号”是指由Kabat et al.,U.S.Dept.of Health and Human Services在“Sequence of Proteinsof Immunological Interest”(1983)提出的编号系统。抗体还可以用EU或Chothia编号系统。
“治疗”是指治疗性治疗和预防性或防治性措施，其目的是预防、减缓、改善和停止不良的生理改变或紊乱，例如疾病的进程，包括但不限于以下无论是可检测还是不可检测的结果，症状的缓解、疾病程度的减小、疾病状态的稳定(即不恶化)、疾病进展的延迟或减缓、疾病状态的改善或缓和，减轻或消失(无论是部分还是全部)、延长与不接受治疗时预期的生存期限等。需要治疗的患者包括已经患有病症或紊乱的患者，容易患有病症或紊乱的患者，或者需要预防该病症或紊乱的患者，可以或预期从施用本发明公开的抗体或组合物用于检测、诊断过程和/或治疗中受益的患者。
“患者”指需要诊断、预后或治疗的任何哺乳动物，包括人类、狗、猫、豚鼠、兔子、大鼠、小鼠、马、牛等。
“约”指相关技术领域技术人员容易知道的相应数值的常规误差范围。在一些实施方式中，本文中提到“约”指所描述的数值以及其±10％、±5％或±1％的范围。
“有效量”是指能引起组织、系统、动物、个体或人类的在生物学或医学上反应的活性化合物或药剂的量。
如本文所用，短语“有需要”是指已将患者鉴定为需要特定方法或治疗。在一些实施例中，可以通过任何诊断方式进行识别。
抗体的制备
可以按常规方法根据本文所述抗体氨基酸序列设计合成编码抗体的DNA，将其置 入表达载体中，然后转染宿主细胞，在培养基中培养被转染的宿主细胞产生单克隆抗体。在一些实施方案中，表达抗体载体包括至少一个启动子元件，抗体编码序列，转录终止信号和polyA尾。其他元件包括增强子，Kozak序列及插入序列两侧RNA剪接的供体和受体位点。可以通过SV40的前期和后期启动子，来自逆转录病毒的长末端重复序列如RSV、HTLV1、HIVI及巨细胞病毒的早期启动子来获得高效的转录，也可应用其它一些细胞的启动子如肌动蛋白启动子。合适的表达载体可包括pIRES1neo，pRetro-Off，pRetro-On，PLXSN，或者pLNCX，pcDNA3.1(+/-)，pcDNA/Zeo(+/-)，pcDNA3.1/Hygro(+/-)，PSVL，PMSG，pRSVcat，pSV2dhfr，pBC12MI和pCS2等。常使用的哺乳动物细胞包括HEK293细胞，Cos1细胞，Cos7细胞，CV1细胞，鼠L细胞和CHO细胞等。
本文中引用的所有出版物、专利和专利申请全部内容通过参考并入本文用于所有目的。
具体实施方式
以下通过具体的实施例进一步说明本发明的技术方案，具体实施例不代表对本发明保护范围的限制。其他人根据本发明理念所做出的一些非本质的修改和调整仍属于本发明的保护范围。
下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
实施例1抗VEGF抗体的序列
抗VEGF抗体(BAT5906)的氨基酸序列见表1。
表1抗体BAT5906的氨基酸序列
Figure PCTCN2022107388-appb-000009
Figure PCTCN2022107388-appb-000010
实施例2恒河猴脉络膜新生血管抑制实验
在D1-D21(第1-21天)，对恒河猴采用双眼眼底激光诱导脉络膜新生血管形成、构建AMD模型(昭衍(苏州)新药研究中心有限公司)，D22挑选有4级渗漏光斑的动物入组，根据4级光斑平均渗漏面积和4级光斑率进行平均分组，分组及给药方式见表2。渗漏评级的4个等级：1级、光斑没有出现高荧光；2级、光斑高荧光但没有荧光渗漏；3级、光斑高荧光，轻度荧光渗漏，渗漏不超过光斑边缘；4级、光斑高荧光，重度荧光渗漏，渗漏超过光斑边缘。
试验期间每天观察所有动物一次，观察死亡、发病、呼吸、分泌物、粪便以及饮食、饮水情况等。筛选时、D21、D29、D36称取动物体重。所有动物在筛选时、造模前、D21、D24、D29、D36使用裂隙灯观察动物双眼眼前节(结膜、角膜、前房、虹膜、瞳孔、晶状体等)的变化，记录检查结果。所有动物在筛选时，造模后即刻(D1，只进行眼底照相)、D21、D29、D36进行FP(眼底照相)和FFA(眼底荧光造影)检查。所有动物在筛选时，D21、D29、D36进行OCT(光相干断层成像)检查，检查区域需覆盖所有激光光凝斑。
荧光渗漏面积改善率＝荧光渗漏面积减少量/给药前荧光渗漏面积×100％，荧光渗漏面积减少量＝给药前荧光渗漏面积－给药后荧光渗漏面积。
表2分组与给药方式
Figure PCTCN2022107388-appb-000011
Figure PCTCN2022107388-appb-000012
1)试验期间所有动物的临床观察均未见异常，体重均未见异常变化。
2)如表3所示，巴替非班及抗体BAT5906和巴替非班联合给药能减少荧光渗漏面积。
表3第36天的荧光渗漏面积改善率(部分实验数据)
Figure PCTCN2022107388-appb-000013
实施例3激光诱导的恒河猴脉络膜新生血管增生模型玻璃体注射受试物的药效学研究
挑选
Figure PCTCN2022107388-appb-000014
恒河猴(普通级)进行CNV造模，造模后3周，根据四级荧光渗漏情况，随机分成5组(10只，包括溶媒对照组)，每组2只动物，分组及给药方式见表4，给药当天命名为Day1(即D1)。在适应期、造模期及实验期间对所有动物进行详细临床观察；在造模前、给药前(造模后2周，D-1)、给药后D7、D14对所有存活实验动物进行眼刺激检测、眼科检查、眼底检测(眼底拍照、OCT和FFA检查)。
表4试验设计表
Figure PCTCN2022107388-appb-000015
Figure PCTCN2022107388-appb-000016
注：*巴替非班+BAT5906组、巴替非班+阿柏西普组为两种药物联合用药，需在给药前进行混合后，再对受试眼玻璃体注射；溶媒对照组、BAT5906组、阿柏西普组给药体积为50μL/眼，巴替非班+BAT5906组、巴替非班+阿柏西普组给药体积为100μL/眼。
眼刺激检测
在适应期和造模期，各组动物的眼刺激评价均为无刺激性。在给药期，动物#202(BAT5906组)和动物#303(巴替非班+BAT5906组)双眼在D7均有轻微刺激性，在D14检查时恢复正常；动物#301(巴替非班+BAT5906组)在D7出现左眼眼内炎，直至动物实验结束未恢复，可能为该动物眼球较小，玻璃体注射制剂体积较大(100μL)引起的眼内组织水肿等症状所致，右眼轻微刺激性，D14检测恢复；其余动物在给药期均无刺激性。
眼科检查
在适应期和造模期：所有存活动物的眼科检查中均无异常症状。
在给药间：动物#202和动物#303双眼角膜在D7均有轻微混浊，在D14检查时恢复正常；动物#403(阿柏西普组)左眼轻微房水闪辉，在D14检查时恢复正常；动物#301左眼(巴替非班+BAT5906组)在D7出现暗红色结膜充血、角膜重度混浊、中度房水闪辉，无法观察眼底结构等炎症现象，直至动物实验结束未恢复，可能为该动物眼球较小，玻璃体注射制剂体积较大(100μL)引起的眼内组织水肿等症状所致；其余动物在给药期眼科检查中均无异常症状。
眼底检测结果
视网膜及脉络膜厚度总结见表5、表6和图1、图2，荧光渗漏面积和强度总结见表7、表8和图3、图4。
表5视网膜厚度
Figure PCTCN2022107388-appb-000017
注：％diff＝(Day n-Pre-dose)/Pre-dose*100；Pre-dose：给药前；*301动物左眼在给药后出现眼内炎症，后续眼底检测数据不可用。
表6脉络膜厚度
Figure PCTCN2022107388-appb-000018
Figure PCTCN2022107388-appb-000019
注：％diff＝(Day n-Pre-dose)/Pre-dose*100；pre-dose：给药前；*301动物左眼在给药后出现眼内炎症，后续眼底检测数据不可用。
表7荧光渗漏面积变化
Figure PCTCN2022107388-appb-000020
注：％diff＝(Day n-Pre-dose)/Pre-dose*100；Pre-Laser：造模前；Pre-dose：给药前；*301动物左眼在给药后出现眼内炎症，后续眼底检测数据不可用。
表8荧光渗漏强度变化
Figure PCTCN2022107388-appb-000021
Figure PCTCN2022107388-appb-000022
注：％diff＝(Day n-Pre-dose)/Pre-dose*100；Pre-dose：给药前；*301动物左眼在给药后出现眼内炎症，后续眼底检测数据不可用。
(1)视网膜厚度：各组动物造模后均呈现厚度的增长，而在给药后视网膜厚度的修复变化由高至低依次为巴替非班+BAT5906组、巴替非班+阿柏西普组、BAT5906组、溶媒对照组、阿柏西普组。除了视网膜随试验进程自身恢复外，说明巴替非班+BAT5906组、巴替非班+阿柏西普组、BAT5906组三种在给药后对视网膜具有一定的修复功能。
(2)脉络膜厚度：各组动物造模给药后，脉络膜厚度具有呈现一定程度的损伤，而在给药后脉络膜厚度变化修复变化由高至低为巴替非班+BAT5906组、BAT5906组、巴替非班+阿柏西普组、溶媒对照组、阿柏西普组，其中巴替非班+BAT5906组修复最佳，BAT5906组和巴替非班+阿柏西普组次之，溶媒对照组和阿柏西普组表现较为一致。
(3)荧光渗漏变化：各组造模后逐渐出现荧光渗漏现象(由脉络膜新生血管增生引起)，在给药后各组荧光渗漏变化(包括面积和强度)一致修复表现为巴替非班+BAT5906>巴替非班+阿柏西普>BAT5906，巴替非班+阿柏西普与BAT5906相似，单独给予阿柏西普与溶媒对照组相似。
上述结果变化，说明各给药组恒河猴在给药后视网膜厚度、脉络膜厚度、荧光渗漏症状均会出现不同程度的恢复及改善。除了自身进程修复外，巴替非班+BAT5906组、巴替非班+阿柏西普组和BAT5906组对动物模型引起的症状均有较好的修复改善作用，其中以巴替非班+BAT5906组效果最佳。

Claims (34)

  1. 整合素GPIIb/IIIa拮抗剂在制备用于治疗眼类疾病的药物中的用途。
  2. VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂在制备用于治疗眼类疾病的药物组合物中的用途。
  3. VEGF拮抗剂在制备和整合素GPIIb/IIIa拮抗剂联合用于治疗眼类疾病的药物中的用途。
  4. 整合素GPIIb/IIIa拮抗剂或包含整合素GPIIb/IIIa拮抗剂的药物组合物，用于制备增强VEGF拮抗剂治疗眼类疾病的效果的药物中的用途。
  5. 一种试剂盒，其包含VEGF拮抗剂、整合素GPIIb/IIIa拮抗剂，以及用于指导有需要患者给药VEGF拮抗剂、整合素GPIIb/IIIa拮抗剂的说明书。
  6. 治疗眼类疾病的药物组合物，包含VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂。
  7. 如权利要求6所述的药物组合物，其中VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂的质量比为(0.5-7):1，或为(1-7):1，或为(1-4):1，或为1:1，2:1或4:1。
  8. 如权利要求2-7任一项所述的用途，试剂盒，或药物组合物，所述VEGF拮抗剂选自抗VEGF抗体或抗原结合片段、抗VEGF受体抗体或抗原结合片段、VEGF受体融合蛋白、与VEGF特异性结合的适体和VEGFR酪氨酸激酶抑制剂。
  9. 如权利要求8所述的用途，试剂盒，或药物组合物，所述抗VEGF抗体选自布洛赛珠单抗、贝伐珠单抗和雷珠单抗。
  10. 如权利要求8所述的用途，试剂盒，或药物组合物，所述VEGF受体融合蛋白选自阿柏西普和康柏西普。
  11. 如权利要求8所述的用途，试剂盒，或药物组合物，所述VEGFR酪氨酸激酶抑制剂选自：4-(4-溴-2-氟苯胺基)-6-甲氧基-7-(1-甲基哌啶-4-基甲氧基)喹唑啉、4-(4-氟-2-甲基吲哚-5-基氧基)-6-甲氧基-7-(3-吡咯烷-1-基丙氧基)喹唑啉、伐他拉尼、semaxaminib和舒尼替尼。
  12. 如权利要求8所述的用途，试剂盒，或药物组合物，所述抗VEGF抗体或抗原结合片段包含SEQ ID NO:1所示的HCDR1、SEQ ID NO:2所示的HCDR2、SEQ ID NO:3所示的HCDR3、SEQ ID NO:4所示的LCDR1、SEQ ID NO:5所示的LCDR2和SEQ ID NO:6所示的LCDR3。
  13. 如权利要求12所述的用途，试剂盒，或药物组合物，所述抗VEGF抗体或抗原结合片段包含重链可变区和/或轻链可变区；其中，所述重链可变区包含SEQ ID NO:7 所示的序列，或与SEQ ID NO:7所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:7所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列；和/或所述轻链可变区包含SEQ ID NO:8所示的序列，或与SEQ ID NO:8所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:8所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列。
  14. 如权利要求13所述的用途，试剂盒，或药物组合物，所述抗VEGF抗体的重链包含SEQ ID NO:9所示的序列，或与SEQ ID NO:9所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:9所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列；和/或
    所述抗VEGF抗体的轻链包含SEQ ID NO:10所示的序列，或与SEQ ID NO:10所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:10所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列。
  15. 如权利要求1-14任一项所述的用途，试剂盒，或药物组合物，所述整合素GPIIb/IIIa拮抗剂为巴替非班或其药学上可接受的盐。
  16. 如权利要求1-4、8-15任一项所述的用途，所述眼类疾病为VEGF过表达的眼类疾病。
  17. 如权利要求1-4、8-15任一项所述的用途，所述眼类疾病选自黄斑变性、年龄相关性黄斑变性、角膜新生血管形成、与角膜新生血管形成相关的疾病、视网膜新生血管形成、与视网膜/脉络膜新生血管形成相关的疾病、病理性近视继发脉络膜新生血管、虹膜新生血管形成、眼内新生血管形成、眼新生血管病、新生血管性青光眼、黄斑水肿、糖尿病性黄斑水肿、囊样黄斑水肿、视网膜病、糖尿病性视网膜病变、其他缺血相关的视网膜病、早产儿视网膜病、家族性渗出性玻璃体视网膜病、高血压视网膜病、视网膜静脉阻塞、视网膜分枝静脉阻塞、视网膜中央静脉阻塞、CNV、病理性近视、希佩尔-林道病、冠茨病、诺里病、骨质疏松症-假神经胶质瘤综合征、结膜下出血，发红、色素性视网膜炎、视网膜血管瘤增生、黄斑毛细管扩张、视网膜变性、血管炎、视盘水肿、视网膜炎、结膜炎、利伯先天性黑矇、葡萄膜炎、脉络膜炎、眼组织胞浆菌病、眼睑炎、干眼、外伤性眼损伤和舍格伦病。
  18. 一种用于治疗眼类疾病的方法，其包括：向有需要的患者施用有效量的整合素GPIIb/IIIa拮抗剂。
  19. 一种用于治疗眼类疾病的方法，其包括：向有需要的患者施用有效量的VEGF拮抗剂和整合素GPIIb/IIIa拮抗剂。
  20. 如权利要求19所述的方法，其中施用VEGF拮抗剂和整合素GPIIb/IIIa拮抗 剂的质量比为(0.5-7):1，或为(1-7):1，或为(1-4):1，或为1:1，2:1或4:1。
  21. 如权利要求19或20所述的方法，所述VEGF拮抗剂选自抗VEGF抗体或抗原结合片段、抗VEGF受体抗体或抗原结合片段、VEGF受体融合蛋白、与VEGF特异性结合的适体和VEGFR酪氨酸激酶抑制剂。
  22. 如权利要求21所述的方法，所述抗VEGF抗体选自布洛赛珠单抗、贝伐珠单抗和雷珠单抗。
  23. 如权利要求21所述的方法，所述VEGF受体融合蛋白选自阿柏西普和康柏西普。
  24. 如权利要求21所述的方法，所述VEGFR酪氨酸激酶抑制剂选自：4-(4-溴-2-氟苯胺基)-6-甲氧基-7-(1-甲基哌啶-4-基甲氧基)喹唑啉、4-(4-氟-2-甲基吲哚-5-基氧基)-6-甲氧基-7-(3-吡咯烷-1-基丙氧基)喹唑啉、伐他拉尼、semaxaminib和舒尼替尼。
  25. 如权利要求21所述的方法，所述抗VEGF抗体或抗原结合片段包含SEQ ID NO:1所示的HCDR1、SEQ ID NO:2所示的HCDR2、SEQ ID NO:3所示的HCDR3、SEQ ID NO:4所示的LCDR1、SEQ ID NO:5所示的LCDR2和SEQ ID NO:6所示的LCDR3。
  26. 如权利要求25所述的方法，所述抗VEGF抗体或抗原结合片段包含重链可变区和/或轻链可变区；其中，所述重链可变区包含SEQ ID NO:7所示的序列，或与SEQ ID NO:7所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:7所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列；和/或所述轻链可变区包含SEQ ID NO:8所示的序列，或与SEQ ID NO:8所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:8所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列。
  27. 如权利要求26所述的方法，所述抗VEGF抗体的重链包含SEQ ID NO:9所示的序列，或与SEQ ID NO:9所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:9所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列；和/或
    所述抗VEGF抗体的轻链包含SEQ ID NO:10所示的序列，或与SEQ ID NO:10所示序列相比具有至少80％同一性的序列，或与SEQ ID NO:10所示序列相比具有一个或多个保守氨基酸取代的氨基酸序列。
  28. 如权利要求18-27任一项所述的方法，所述整合素GPIIb/IIIa拮抗剂为巴替非班或其药学上可接受的盐。
  29. 如权利要求28所述的方法，每个治疗周期内巴替非班或其药学上可接受的盐给药的有效量为0.1mg至6mg。
  30. 如权利要求28所述的方法，巴替非班或其药学上可接受的盐的每次给药量为0.1mg/眼-3mg/眼。
  31. 如权利要求19-30任一项所述的方法，每个治疗周期内VEGF拮抗剂给药的有效量为0.1mg至15mg。
  32. 如权利要求19-30任一项所述的方法，所述VEGF拮抗剂的每次给药量为0.1mg/眼-7.5mg/眼，或为1mg/眼-7.5mg/眼，或为1mg/眼-4mg/眼。
  33. 如权利要求18-32任一项所述的方法，所述眼类疾病为VEGF过表达的眼类疾病。
  34. 如权利要求18-32任一项所述的方法，所述眼类疾病选自黄斑变性、年龄相关性黄斑变性、角膜新生血管形成、与角膜新生血管形成相关的疾病、视网膜新生血管形成、与视网膜/脉络膜新生血管形成相关的疾病、病理性近视继发脉络膜新生血管、虹膜新生血管形成、眼内新生血管形成、眼新生血管病、新生血管性青光眼、黄斑水肿、糖尿病性黄斑水肿、囊样黄斑水肿、视网膜病、糖尿病性视网膜病变、其他缺血相关的视网膜病、早产儿视网膜病、家族性渗出性玻璃体视网膜病、高血压视网膜病、视网膜静脉阻塞、视网膜分枝静脉阻塞、视网膜中央静脉阻塞、CNV、病理性近视、希佩尔-林道病、冠茨病、诺里病、骨质疏松症-假神经胶质瘤综合征、结膜下出血，发红、色素性视网膜炎、视网膜血管瘤增生、黄斑毛细管扩张、视网膜变性、血管炎、视盘水肿、视网膜炎、结膜炎、利伯先天性黑矇、葡萄膜炎、脉络膜炎、眼组织胞浆菌病、眼睑炎、干眼、外伤性眼损伤和舍格伦病。
PCT/CN2022/107388 2021-07-23 2022-07-22 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 WO2023001288A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110837945.9 2021-07-23
CN202110837945 2021-07-23

Publications (1)

Publication Number Publication Date
WO2023001288A1 true WO2023001288A1 (zh) 2023-01-26

Family

ID=84978928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/107388 WO2023001288A1 (zh) 2021-07-23 2022-07-22 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用

Country Status (2)

Country Link
CN (1) CN116059312A (zh)
WO (1) WO2023001288A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024193567A1 (zh) * 2023-03-21 2024-09-26 百奥泰生物制药股份有限公司 一种复方制剂及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003933A1 (en) * 2004-06-04 2006-01-05 Martin Friedlander Compositions and methods for treatment of neovascular diseases
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20130129621A1 (en) * 2009-11-10 2013-05-23 Allegro Pharmaceuticals, Inc. Integrin Receptor Antagonists and Their Methods of Use
US20160002612A1 (en) * 2013-02-18 2016-01-07 Vegenics Pty Limited Ligand binding molecules and uses thereof
CN108137681A (zh) * 2015-09-23 2018-06-08 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
CN110891611A (zh) * 2017-03-22 2020-03-17 基因泰克公司 水凝胶交联透明质酸前药组合物和方法
CN112805284A (zh) * 2018-08-17 2021-05-14 奥克斯润有限责任公司 整合素拮抗剂

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003933A1 (en) * 2004-06-04 2006-01-05 Martin Friedlander Compositions and methods for treatment of neovascular diseases
US20130129621A1 (en) * 2009-11-10 2013-05-23 Allegro Pharmaceuticals, Inc. Integrin Receptor Antagonists and Their Methods of Use
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20160002612A1 (en) * 2013-02-18 2016-01-07 Vegenics Pty Limited Ligand binding molecules and uses thereof
CN108137681A (zh) * 2015-09-23 2018-06-08 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
CN110891611A (zh) * 2017-03-22 2020-03-17 基因泰克公司 水凝胶交联透明质酸前药组合物和方法
CN112805284A (zh) * 2018-08-17 2021-05-14 奥克斯润有限责任公司 整合素拮抗剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU YUAN;SHI AI-XIN: "Pharmacological and Clinical Evaluation of Lymphocyte Function-associated Antigen-1 Inhibitor, Lifitegrast Ophthalmic Solution", CHINESE JOURNAL OF NEW DRUGS, vol. 26, no. 10, 1 June 2017 (2017-06-01), pages 1105 - 1109, XP093027248, ISSN: 1003-3734 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024193567A1 (zh) * 2023-03-21 2024-09-26 百奥泰生物制药股份有限公司 一种复方制剂及其应用

Also Published As

Publication number Publication date
CN116059312A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
US20200231703A1 (en) Treatment of ocular disease
JP7273204B2 (ja) 眼科疾患の処置
US11136389B2 (en) Humanized monoclonal antibodies that target VE-PTP (HPTP-β)
AU2007238677B2 (en) Use of IL-I antibodies for treating ophthalmic disorders
DK2575881T3 (en) Specific anti-CD160-antibodies for the treatment of eye diseases on the basis of neoangiogenesis
AU2019374780A1 (en) Methods of treating Graves' ophthalmopathy using anti-FcRn antibodies
WO2023001288A1 (zh) 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用
WO2020022438A1 (ja) 網膜線維化を伴う眼疾患の処置剤
WO2022242757A1 (zh) 抗pd-1抗体的应用
WO2024114641A1 (en) C5/vegf bispecific binding molecules
WO2024153189A1 (zh) 一种复方制剂及其应用
WO2024052357A1 (en) Methods of treating graves' disease using anti-fcrn antibodies
CN115702931A (zh) 抗pd-l1/cd47双特异抗体在治疗疾病中的应用
NZ623275B2 (en) Treatment of ocular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22845451

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22845451

Country of ref document: EP

Kind code of ref document: A1